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Abstract 
The current study investigated the effect of interferon-α (IFN-α) on the cochlear cell line 
to shed light on the mechanisms by which interferon alpha may affect hearing. HEI-OC1 cell line 
and real time-PCR were used to determine the expression of those genes that might be involved 
in these mechanisms. Dose- (20, 40, & 80 U/ml) and time-dependent experiment-1 did not show 
significant alteration in gene expression associated with the stimulations of the IFN-α receptors. 
Therefore, a second experiment was planned. A 3 X 4 factorial design, consisting of three 
treatment conditions (0, 200 & 2000U/ml) and four time-points (6, 12, 24 & 48 Hrs), was 
employed. The results of experiment-2 revealed that significant differential expression of 
inflammatory genes, immune response genes and apoptotic genes is found in a dose- and time-
dependent manner. This outcome indicates that IFN-α treatment led to initiation of an 
inflammatory response, an immune response and apoptosis of the cochlear cells, which was 
confirmed by a reduction in cell viability. The immune response was the most pronounced 
response; whereas inflammatory the apoptotic responses were transient.  
Therefore, the current in-vitro study indicates that the inflammatory response, the 
immune response and apoptosis might be the underlying mechanisms involved in the hearing 
impairment previously reported in patients under IFN-α therapy. These results imply that pre-
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 v 
treatment hearing evaluation as well as close monitoring of hearing function in patients 
undergoing long-term high-dose of IFN-α therapy are necessary to avoid or to minimize its 
adverse effect on hearing. The results also indicate that there is a need for further investigation of 
other markers that might be involved in signaling pathways of IFN-α, including markers for 
intrinsic pathway of apoptosis and antiapoptotic markers as well as markers for necrosis. This 
information might open an avenue for therapeutic intervention that can protect the inner ear from 
the ototoxic effect of some medications in general and IFN-α in particular and treat some 
immune-mediated inner ear disorders. In addition, this information might help in identifying 
novel diagnostic markers for vulnerability, severity, and outcomes of any cochlear pathology. 
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1.0  CHAPTER I: INTRODUCTION 
Interferons (IFNs) are a family of natural proteins secreted in small amounts mainly by 
the cells of the immune system in  response to viral infections, bacterial infections and tumors. 
There are many types of IFNs; however, the most common in the clinical field are interferon-
alpha (IFN-α), interferon-beta (IFN-β) and interferon-gama (IFN-γ). Interferons have many 
biological properties such as modification of inflammatory response, modification of immune 
response, and inhibition of cell proliferation (they stop cell growth or lead to cell death, 
apoptosis). Therefore, they are widley used clinically in the treatment of many diseases. For 
example, they are used in treatment of viral hepatitis C and hepatitis B, multiple sclerosis and  
regression of a number of malignant tumors.   
Although IFNs have been successful as potent antivirals, immunomodulators and 
anticancer agents, treatment with IFN carries significant risks (Heathcote & Main, 2005). Many 
side effects have been reported with IFN therapy, including flu-like symptoms, depression, 
autoimmune reactions (Benelhadj, Marcellin, Castelnau, et al., 1997), and some blood disorders 
(Poynard, Bedossa, Chevallier, et al., 1995).  
Recently, there are a considerable number of studies that have found an association 
between hearing impairment and IFN therapy, in particular with IFN-α  (Atug, Akin, Yilmaz, 
Sari, Tozun (2009); Cadoni, Marinelli, De Santis, Romito, Manna, et al., 1998; Elloumi, 
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Houissa, Bel Hadj, Gargouri, Romani, Kharrat, & Ghorbel, 2007; Formann, Stauber, Denk, 
Jessner, Zollner, et al., 2004; Johnson, Sargent, Galizio, and Ubogu, 2008; Kanda, Shigeno, 
Kinoshita, Nakao, Yano, et al.,1994; Okanoue, Sakamoto, Itoh, Masahito, Yasui, et al., 1996; 
Piekarska; Jozefowicz-Korczynska; Wojcik; & Berkan; 2007; Sachar and Polio, 2004; Salkic, 
Zerem, Zildzic, & Basic, 2009; Wong, Cheong-Lee, Ford, Yoshida, 2005). The incidence of 
hearing impairment due to IFN was reported more frequently in patients with hepatitis C than in 
patients receiving IFN for other diseases.  
On the other hand, a few studies showed no affect of IFN on hearing. For example, 
Kaygusuz, Ozturk Kaygusuz, Ozturk, Kilic, et al., (2004) found no effect of IFN-α on the 
hearing threshold of patients with chronic active hepatitis. In addition, Akyol, Sarac, Akyol, et 
al., (2001) found no histopathological changes in the organ of Corti of the cochlea of albino 
Swiss mice treated with a single dose of IFN; yet the auditory brainstem showed significant 
changes.  
The inconsistency in findings was not  limited to the absence of the affect of IFN on 
hearing. There is also inconsistency with regard to effectiveness of IFNs to treat sensorineural 
hearing loss (SNHL), especially that of viral or autoimmune origin (Kanemaru, Fukushima, 
Nakamura, et al., (1997). 
The current study was designed to evaluate the incocsistency in the effect of IFN-α on the 
auditory system. This incosistency among the findings implies the need for a well-controlled 
study at the cellular level (using methods of molecular biology) to determine if this contradiction 
is a matter of mechanism(s) or simply dose-dependent effects. In particular, there is a need to 
know when IFN can be pathologic to the organ of hearing rather than (potentially) protective or 
therapeutic. Second, from a clinical point of view, because IFNs are widely used today in the 
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clinical arena, it is important to ensure the safety of such medications in order to avoid 
subsequent handicap (in this case hearing impairment). Regular monitoring of the hearing 
function might be required in those patients who are receiving IFNs, but the underlying 
mechanisms first must be explored.  
In general, understanding the molecular and cellular signals that regulate and control the 
effect of IFNs on the cochlear structures will help in understanding the origin and mechanism of 
many inner ear diseases, especially that of autoimmune origin. It also might lead to developing 
effective methods for preventing unwanted side effects on the inner ear and opening an avenue 
for new therapeutic agents to manage many inner ear disorders. In addition, it might help in 
identifying novel diagnostic markers for vulnerability, severity, and outcomes of any cochlear 
pathology. 
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2.0  CHAPTER II: REVIEW OF THE LITERATURE 
2.1 BACKGROUND 
Interferons (IFNs) are members of the cytokines’ family, a large group of proteins 
secreted by the cells of the immune system (Isaacs and Lindenmann, 1957). Cytokines, including 
IFNs, form a communication network to help the cells of the immune system perform their 
functions. Cells of the immune system are not localized in a specific organ; rather, they are 
peripatetic. In other words, within the immune system, there are cells that first detect 
inflammatory stimuli, cells that present antigen to lymphocytes, and cells that clear the antigen 
and repair tissue damage. In addition, the lymphocytes sometimes wander the body in the blood 
stream, sometimes traffic through the organs and tissues, and sometimes are localized in the 
lymphoid tissues. This dynamic feature of the immune system cells makes it difficult for them to 
communicate and to perform their function in developing a rapidly integrated response to any 
antigen in any part of the body. Therefore, cytokines, by their unique characteristics, can help 
these cells to act locally or remotely, specifically or globally, and transiently or continuously. 
The unique characteristics of cytokines that make them a perfect communication network for the 
cells of the immune system can be summarized as follows: 
- Most cytokines are small-sized molecules made of polypeptides or glycoproteins. 
- The same cytokine may be made by a number of different cells.  
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- Likewise, the same cytokine may act on different cells (pleiotropic actions), including 
cells of the immune system and inflammatory-modulating cells.  
- Cytokines have considerable redundancy in that many of them can share similar 
functions. 
- Cytokines often are produced in a cascade (sequence of events with one event leading to 
another), as one cytokine stimulates its target cells to make additional cytokines.  
- Cytokines act synergistically (which means that two or more cytokines act together) or 
antagonistically (which means that cytokines are working in opposition to one another). 
Since cytokines in general and interferons in particular originate from, exert their effects on, 
and communicate between the cells of the immune system, it is helpful to give an overview of 
some of the important points about the immune system, its cellular components, and its function. 
2.1.1 The immune system 
The immune system is considered a part of the hematopoietic system, in which the 
cellular components of the blood are manufactured and differentiated. Briefly, all blood cells 
originate from a pluripotent stem cell (i.e., a cell that has multiple potentials to differentiate to 
other stem cells or progenitors) in bone marrow (Figure 1). These progenitors include the 
erythroid progenitor, the myeloid progenitor and the lymphoid progenitor.  
While the erythroid progenitor differentiates to form red blood cells and blood platelets, 
the myeloid progenitor differentiates to form the myeloid linage of white blood cells or 
leukocytes (Figure 2.2), which include the following cells:  
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- Neutrophils that are specialized to engulf and kill microorganisms through a process 
called phagocytosis.  
- Eosinophils that defend against parasites. 
- Basophiles that help to alleviate some allergic reactions.  
- Monocytes that circulate in the blood or migrate to tissue where they form tissue 
macrophages, the main phagocytic cells of the immune system in case of infection or 
inflammation.  
- Dendritic cells (DCs or antigen presenting cells APCs) that present degraded or intact 
antigen to cells that are specified to kill or engulf that antigen. 
- Mast cells that make major contributions to hypersensitivity and inflammatory reactions.  
The lymphoid progenitor (Figure 2) gives rise to form the lymphoid linage of white blood 
cells, which constitute the main cells of the immune system. There are three distinguished 
populations of lymphocytes: 
- Natural killer cells (NK). 
- B- Lymphocytes (B-cells).  
- T- Lymphocytes (T-cells). 
While NK cells, along with the cells of the myeloid linage, play an important role in innate 
immunity, both B-cells and T-cells are responsible for adaptive immunity. Although both B and 
T cells originate from the lymphoid progenitor in the bone marrow, B cells complete their 
maturation there before entering the blood, but T cells migrate to the thymus where they 
complete their maturation (Mayer, 2006). The mature lymphocytes are able to differentiate the 
self antigen (the body’s own tissue) from foreign antigen on subsequent exposure, and afterward 
they are allowed to leave the primary lymphatic organs (bone marrow and thymus) to enter the  
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Figure 1: Development of the cells of the immune system 
            www.allthingsstemcell.com/tag/hematopoietic/ 
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blood. Failure of lymphocytes in differentiating self antigens from foreign antigens will lead to a 
breakdown of the self tolerance and developing of autoimmune reaction to the body’s own 
tissue. During their circulation in the blood and traveling into secondary lymphatic organs 
(spleen, lymph nodes), lymphocytes encounter foreign antigens brought from a site of infection.  
On exposure to foreign antigen, the naïve B-cells differentiate to form plasma cells, 
which secrete numerous amounts of antibodies that are specific to that antigen. Likewise, on 
exposure to foreign antigen, the naïve T-cells will be activated into effector T-cells, namely T-
helper lymphocytes (Th) or CD4+ T-cells and cytotoxic T-cells or CD8+ T-cells. T-helper 
lymphocyte (Th) or CD4+ cells, include T-helper-1(Th1) and T-helper-2 (Th2). They are called 
helper because they are specialized to help other cells of the immune system to respond to 
extracellular organisms. While Th1 cells activate macrophage to phagocyte and kill extracellular 
organisms and secrete cytokines such as IFN-gamma (IFN-γ); Th2 cells help B-lymphocytes to 
produce antibodies. The second type of the effector T-cells is the cytotoxic T-cells or CD8+ T-
cells, which kill cells infected with viruses and other intracellular pathogens. The term “CD” 
stands for “clusters of differentiation”. The “CD” glycoproteins present on the cell surface and 
act as coreceptors (molecules that activate the receptors).  
The cells of the immune system interact with each other to provide different defense 
mechanisms against microorganisms or any foreign body; most of these interactions are 
accomplished via different members of cytokines. The following section will overview these 
defense mechanisms.  
  
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
        
Figure 2: Cells of the immune system 
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2.1.2 Role of the immune system in the body’s defense  
In response to any microorganism or foreign antigen, the immune system has three layered lines 
of defense with increased selectivity, including the skin as a surface barrier of the body, the 
innate immunity and the adaptive immunity. Normally, the surface epithelia provide a barrier 
against entry of most of the pathogens to the interior of the body.  However, if the pathogen is 
successful in penetrating the surface epithelia, it will be faced by the effector cells of the innate 
immunity; the mechanisms of which are determined entirely by the genes carried by the person. 
The response of the innate immunity is fixed, fast, and non-selective and it is usually effective in 
controlling most of the infection. An essential response to invasion by a foreign antigen is the 
inflammatory response. This response occurs in response to bacterial infection, and it is mediated 
by the cells of the innate immunity, which include phagocytes (macrophages, neutrophils, and 
DCs), mast cells, eosinophils, basophiles, and NK cells. The inflammatory response includes 
release of inflammatory mediators that attract more inflammatory cells to the site of infection, 
phagocytosis, and death of the inflammatory cells as well as cells of the injured tissue followed 
by tissue repair and scaring (Martin & Leibovich, 2005).  
Pathogens or antigens that escape the innate immunity will be encountered by the 
adaptive immunity which is slow to start but powerful and specific to the invading pathogen 
(Mayer, 2006; Pancer & Cooper, 2006). The adaptive immunity is either by production of 
antibodies (humoral immunity) or induction of cell-mediated response accomplished by B-
lymphocytes and T-lymphocytes, respectively. B-cells are responsible for attacking extracellular 
organisms through their specific antibodies, immunoglobulins (Ig); T-cells, on the other hand, 
attack intracellular organisms or kill infected host cells, using their specific T-cell receptors 
11 
 
(Holtmeir & Kabelitz, 2005). The binding of B-cells to the pathogen through its Ig drives the 
pathogen to inflammatory reaction with subsequent phagocytosis and cell death (Janeway, 
Travers, Walport, & Schlomchik, 2005). The binding of T-helper cells (CD+4) or cytotoxic T 
cells (CD+8) to the microbe or the infected host cells through their receptors will release 
cytotoxins that form pores in the plasma membrane of the target cells, with subsequent entry of 
water and toxins and cell death (Radoja, Frey, & Vukmanovic, 2006). Therefore, the outcome of 
the innate immunity, the inflammatory response, or the adaptive immune response can be cell 
death, by either necrosis or apoptosis. A brief overview on cell death including necrosis and 
apoptosis will be provided in the following section. 
2.1.3 Cell Death (necrosis/apoptosis) 
Two paradigms of cell death can be distinguished: necrosis and apoptosis (Figure 3). Necrosis is 
the prevailing form of cell death, resulting from a non-specific, severe and acute insult to the 
tissues such as sudden anoxia, ischemia, or extreme physical or chemical injury. It is 
characterized by the degradation of cytoplasmic structure and the release of the cellular contents 
into the environment, which then leads to cellular damage of the surrounding cells. Necrosis is 
usually accompanied by a potent inflammatory response in the surrounding tissues (Leist and 
Nicotera, 1998; Leist, Single, Castoldi, Kuhnle, & Nicotera, 1997).  
Apoptosis, or programmed cell death, is a tightly regulated process that is essential 
during embryonic development and adult life to maintain a constant cell number since too much 
or too little apoptosis has been shown to lead to a number of diseases such as diabetes, 
autoimmune and neurodegenerative diseases and cancer (Leist et al., 1997). In other words,  
12 
 
 
 
 
 
 
 
Figure 3: Apoptosis versus necrosis 
Gewies (2003) from: http://www.celldeath.de/encyclo/aporev/aporev.htm 
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apoptosis is responsible for ordered removal of superfluous, aged, or damaged cells (Kroemer, 
Petit, Zamzami, Vayssière, & Mignotte, 1995; Thompson, 1995). Cells undergo apoptosis by 
using two major pathways: the extrinsic or death receptor (DR) pathway and the intrinsic or 
mitochondrial pathway. Both pathways depend on activation and involvement of caspases, which 
are inactive enzymes acting as death effector molecules in response to various types of apoptotic 
stimuli (Debatin and Krammer, 2004). Both pathways are involved in the mechanisms of IFN-
induced cell death and they also can occur in the cochlea as a result of exposure to loud noise or 
ototoxic agents, such as aminoglycosides (Jørgensen, 1991; Li, Nevill, and Forge, 1995) and 
cisplatin (Devarajan, Savoca, Castaneda, Park, Esteban-Cruciani, et al., 2002).  
The extrinsic pathway or death receptor pathway is activated via binding of death 
receptor ligands (molecules that activate the receptors) to their respective receptors. The most 
common cell death pathway is the Fas-Fas ligand (Fas-FasL) pathway (Figure 4). The binding of 
the death receptors to their corresponding ligands results in aggregation and formation of Fas 
activating death domain (FADD), which is followed by activation of caspase-8—upstream 
caspase (they are activated at the beginning of the death pathway). Activation of caspase-8 leads 
to activation of downstream caspases (they are activated later in the pathway), mainly caspase-3 
and its release into the cytoplasm (Danial and Korsmeyer, 2004). Caspase-3 has a proteolytic 
effect (they break down proteins), leading to a cleavage of various intracellular proteins, 
including nuclear proteins, DNA, cytoskeletons, endoplasmic reticulum and cytoplasm; ending 
by cell death (Fraaser and Evan, 1996). 
On the other hand, in the mitochondrial or the intrinsic pathway (Figure 5), the Bcl-2 
family of proteins is responsible for initiating cell death. They are a family of proteins that 
control the permeability of the outer mitochondrial membrane. They are named such because 
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they are associated with the development of B-cell lymphoma type 2 (Bcl-2). Some members of 
this family are proapoptotic (i.e., cause apoptosis), e.g., Bax, BAD, Bak and Bok. Other 
members are anti-apoptotic (e.g., Bcl-xL, and Bcl-w). In response to apoptotic stimuli, Bax and 
Bak molecules will be activated leading to a disturbance in the mitochondrial membrane 
potential, which allows the release of cytochrome c from the inter-membrane mitochondrial 
space to the cytoplasm. Cytochrome c is an essential protein for electron transport through the 
mitochondrial membrane. The release of cytochrome c from the mitochondria leads to activation 
of procaspases-9 (Li, Nijhawan, Budihardjo, Srinivasula, Ahmad, et al., 1997), with subsequent 
activation of caspase-3, caspase-6, and caspase-7. Like the extrinsic pathway, caspase-3 will 
cause the cleavage of various intracellular proteins, including nuclear proteins, proteins of the 
nuclear lamina, cytoskeletons, endoplasmic reticulum and cytoplasm, leading to cell death 
(Fraaser and Evan, 1996). Notably, caspase-3 is a key caspase in apoptosis because it is activated 
in both the extrinsic and the intrinsic pathways and its activation leads to cleavage of most 
intracellular proteins, leading to cell death. 
The inflammatory response, the immune response and apoptosis can be initiated 
anywhere in the body as long as there is access to the cells of the immune system. The inner ear 
is involved in immune reaction, inflammatory reaction as well as apoptosis as a result of viral 
infection, systemic autoimmune disease, e.g., systemic lopus erythrematosis (Khalidi, , Rebello, 
Robertson, 2008) or due to ototoxic agents.  Because IFNs modulate the inflammatory and the 
immune responses and also initiate apoptosis, IFNs can affect the inner ear and cause hearing 
impairment. To illustrate this issue, the next section will shed light on IFNs, their types, their 
sources, their biological effects, their clinical use, their side effects, and their effect on hearing as 
demonstrated by previous studies.   
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Figure 4: Extrinsic (Fas-FasL) of apoptosis 
http://upload.wikimedia.org/wikipedia/commons/f/f5/Fas-signalling.png 
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Figure 5: Intrinsic pathway of apoptosis 
http://www.researchapoptosis.com/apoptosis/pathways/intrinsic/index.m 
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2.2 INTERFERONS 
Interferons (IFNs) are categorized into three types, type I, type II (Aguet, Grobke, & Dreiding, 
1984; Haque & Williams, 1989) and type III (Kotenko, Gallagher, Baurin, Lewis-Antes, Shen, et 
al., 2003; Sheppard, Kindsvogel, Xu, Henderson, Schlutsmeyer, Whitmore, et al., 2003; Vilcek, 
2003). This classification is based on structural homology and cell-surface receptor-binding as 
well as functional activity. Type I IFNs include multiple members, only two of which are widely 
used clinically, interferon-alpha (IFN-α) and interferon-beta (IFN-β). All Type I IFNs (IFN-α & 
IFN-β) bind to the same receptors and are thought to elicit a common set of signaling events that 
ultimately regulates the expression of common biological activities (Petska, Langer, Zoon, & 
Samuel, 1987; Platanias, 1995). However, other studies show that IFN-α and IFN-β sometimes 
produces distinctive activities (Platanias, Uddin, Domanskii, & Colamonici, 1996).  
On the other hand, type II- IFN is called interferon-gamma (IFN-γ) or immune IFN. It is 
distinctive from type I IFNs as it stimulates different types of receptors. Interferon-γ also is used 
clinically (Colonna, Krug, & Cella, 2002); whereas, type III (IFN-λ) has not yet been used 
clinically.  
There is an association between IFNs and hearing impairment. Clinically, hearing 
impairment has been reported in patients treated with type I-IFN (IFN-α & IFN-β). 
Experimentally, type II-IFN (IFN-γ) is associated with autoimmune hearing loss and the 
induction of immune response in the inner ear. To further analyze these findings, an overview of 
both IFNs and their relation to hearing will be provided in the following sections.  
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2.2.1 Sources of IFNs in the body 
Interferon alpha (IFN-α) is produced by many cell types in response to viral infection and 
virtually all cells are equipped to make type I-IFN. The main source, however, is the DCs, which 
play an important role in the immune response. Interferon-γ is secreted by the NK cells, 
macrophages, and T- lymphocytes, mainly CD4 Th1 cells. Since IFN-α is a prominent activator 
of NK cells, Th1 and macrophage, it can enhance the secretion of IFN-γ by these cells (Major, 
Dahari, Mihalik, Puig, Rice, et al., 2004; Tan, Derrick, Hong, Sanda, Grosse, Edenberg, 2005; 
Thimme, Bukh, Spangenberg, Wieland, Pemberton et al., 2002). Therefore, the effects of IFN-α 
on any organ or tissue can either be mediated by its own direct action or by enhancing the 
secretion of IFN-β or IFN- γ. 
2.2.2 Signaling pathway of interferons 
The signaling pathway of interferon is the sequence of events that are followed by IFNs to exert 
their biological activities. Three important terms will be introduced to explain the signaling 
pathway of IFNs; they include IFN receptors, Janus kinases, and STATs.  
2.2.2.1 IFN receptors 
IFN receptors are trans-membranous types of receptors because they are located on the 
surface of the cell and extend through the cell membrane to the cytoplasm, forming a 
cytoplasmic tail (Aguet et al., 1984). They are classified into two classes, class I, which is 
formed of α and β subunits (IFN-αR1 & IFN-αR2) and class II, which is formed of two subunits 
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(IFN-γR1  & IFN-γR2 ), corresponding to IFN-I and IFN-II respectively (Caraglia , Marra , 
Pelaia , Maselli , Caputi , Marsico, & Abbruzzese, 2005). 
2.2.2.2 Janus Kinases 
JAK1, JAK2, and Tyk2 are members of the Janus kinases family, which are enzymes that 
donate phosphate groups to their substrates to be activated (Ihle, Witthuhn, Quelle, Yamamoto, 
Thierfelder, et al., 1994).These kinases are connected to the IFNs’ receptors and hence they will 
be activated once the receptors are activated by IFNs (Leonard, 2001).    
2.2.2.3 STATs  
The STATs are signal transducers and activators of transcription, a family of inactive 
cytoplasmic proteins that are named by the virtue of their novel dual function as they transfer 
signals from the receptors to the nucleus and activate transcription factors after they move to the 
nucleus. Transcription factors are the proteins that are involved in gene expression. There are 
seven known mammalian STAT proteins; only STAT1, STAT2, are involved in the pathway of 
IFN-α/ β and IFN-γ (Chen, Vinkemeier, Zhao, Jeruzalmi, Darnell, & Kuriyan 1998). 
The most common IFN signaling pathway is the JAK-STAT pathway (Figure 6). Briefly, 
when IFN molecules bind to their receptors, the Janus kinases will be activated (Jak1and Tyk-2 
in the case of type I-IFN and Jak1 and Jak2 in the case of type II-IFN), leading to 
phosphorylation and activation of STAT1 and STAT2 (Leonard and  O'Shea, 1998). Both 
STAT1 and STAT2 quickly form homodimers (i.e., forming two identical STATs, STAT1& 
STAT1) in the case of type II-IFN or hetrodimers (i.e., forming two different STATs, STAT1& 
STAT2) in the case of type I-IFN. The activated STAT molecules dissociate from the receptors 
and move to the nucleus (Chatterjee-Kishore, Kishore, Hicklin, Marincola, & Ferrone, 1998), 
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where they bind to a transcription factor called P48 and form a complex called interferon-
stimulated gene factor-3 (ISGF-3). The ISGF-3 will bind to a specific sequence on the gene 
called the interferon stimulated response element (ISRE) in case of type I, and gamma activating 
sequence (GAS) in case of type II-IFN, leading to expression of that gene. Therefore, the 
activation of signaling cascades mediated by IFNs will ultimately result in a new gene expression 
to induce certain biological changes in the target cell (Decker et al., 1991).  
2.2.3 Biological effects of interferons 
Interferons have many biological properties such as modulation of inflammatory response, 
modulation of immune response, and inhibition of cell proliferation (they can stop cell growth or 
lead to cell death). With regard to its effect on inflammatory reaction, interferons have a potent 
antiviral activity, and hence they are widely used in the treatment of many viral infections. 
Nowadays, IFN-α is the cornerstone therapy for chronic viral hepatitis, including hepatitis B and 
hepatitis C. Because of its modulating effect on the immune response, IFN-β, currently, is the 
most widely used therapy for multiple sclerosis (Jacobs, Cookfair, Rudick, Herndon, Richert, et 
al., 1996).  
As an antiproliferative, many studies have shown that IFNs (IFN-α, IFN- β, and IFN- γ) 
can induce the regression of a number of tumors including hairy cell leukemia (Ahmed, Kanti, 
and Rai, 2003), chronic myelogenous leukemia, non-Hodgkin lymphoma (Ezaki, 1996), 
Kaposi’s Sarcoma (Stadler, 1998), renal cell carcinoma (Gleave, Elhilali, Fradet, Davis, Venner,  
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Figure 6: Interferon-mediated Jak-STAT pathway 
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Saad, et al., 1998), malignant melanoma (Balch, Soong, Gershenwald, et al., 2001), and breast 
carcinoma (Kamamura, Takahashi, Komaki, & Monden, 1998).  
Since inflammatory response, immune reaction and cell death are mechanisms by which 
IFNs can induce their effects on any tissue, in general and inner ear in particular, the following 
sections will highlight these mechanisms and their contribution to hearing impairment.   
2.2.3.1 Interferons as inflammatory modulators  
There is increasing evidence that IFN-α/β and IFN-γ interfere with the synthesis or the 
release of other cytokines such as interleukin-1 (IL-1) and prostaglandin (both are primary 
inflammatory cytokines) causing fever and hypotension (Dinarello, 1996; Dinarello, 1984). 
Thus, both IFN-α and IFN-γ can be used as an anti-inflammatory; especially in treatment of 
disease mediated by IL-1 (Browning & Ribolini, 1987).   On the other hand, both IFN-α/β and 
IFN- γ increase the expression of intercellular adhesion molecules (ICAM-1) (Sundelin, Roberg, 
Grenman, & Hakansson, 2007). ICAM-1 molecules are known to enhance the inflammatory 
responses by increasing migration of neutrophils from peripheral blood to the site of 
inflammation. Therefore, the ICAM-1 molecules can be used as a marker for the action of IFN-α 
and IFN- γ as inflammatory modulators. Also it has been found that IFN-α therapy promotes the 
production of TNF-α, which makes TNF-α a marker for the inflammatory response mediated by 
IFN-α (Ren, Jin, Piao, & Piao, 2007). 
2.2.3.2 Interferons as immune modulators  
The contributions of IFNs to the immune response involve the activation of the immune 
system cells as well as the increased secretion of other cytokines that can affect the immune 
response. For instance, IFN-α induces activation of NK cells, which are the key cells in the 
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innate immune response (Biron, Nguyen, Pien, Cousens, & Salazar-Mather, 1999). IFN-α also 
activates CD4+ and CD8+ T-cells and enhances their cytotoxicity, and thus promotes the 
adaptive immune response (York, Odom, Murphy, Ives, and Wente, 1999). Another immune cell 
stimulated by IFN-α is the DC, which is considered a professional APC (Cella, Facchetti, 
Lanzavecchia, & Colonna, 2000). Also, IFN-α and IFN-γ are potent inducers of the major 
histocompatibility complexes (MHC class I and class II), and thus they enhance antigen 
presentation to T cells (Biron, 1998). The MHC molecules are glycoprotein molecules encoded 
by a cluster of closely linked genes that are located on chromosome 6 in human. This region on 
the chromosome is called major histocompatibility complex because it causes T cells to reject 
tissues transplanted from unrelated donors to recipients. The MHC molecules are referred to as 
human leukocytic antigen (HLA) in humans. They are categorized into two classes, class-I and 
class-II, the expression of which is enhanced by IFN-α and IFN-γ, respectively. Hence, an 
increase of the expression of MHC will indicate the immune-modulating effect of IFNs. MHC-I 
molecules encoded by H2K1gene and present on the surface of the APCs, which function to 
hand off processed antigens to phagocytic cells. The APCs break down the antigens into simple 
peptides and use the MHC to present these peptides to phagocytic cells for phagocytosis and 
killing.  
In addition, IFN-α stimulates the expression of other cytokines, which ultimately affects 
the function and activity of many immune cells. The most important cytokine that is regulated by 
IFN-α is interleukin-15 (IL-15), which stimulates NK cell and cytotoxic T cell proliferation, 
leading to enhancement of both innate and adaptive immunity (Zhang, Sun, Hwang, Tough, 
Sprent,1998; Durbin, Hackenmiller, Simon, & Levy, 1996). Stimulation of NK cells by IFN-α 
results in an increased IFN-γ level, which is essential for macrophage activation as well as T cell 
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stimulation (Biron, 1999). Through the activation of the immune system cells and increasing the 
secretion of IL-15 and IFN-γ, IFN-α will be able to initiate a global immune response and 
function as a key modulator of both innate and adaptive immunity.  
From a clinical point of view, IFN-α production is associated with several autoimmune 
diseases, e.g., systemic lupus erythematosus (Farkas, Beiske, Lund-Johansen, Brandtzaeg,& 
Jahnsen, 2001), insulin-dependent diabetes mellitus (Devendra and Eisenbarth, 2004), 
rheumatoid arthritis (Lande, Giacomini, Serafini, Rosicarelli, Sebastiani, et al,. 2004),  psoriasis 
(Nestle FO et al., 2005), and Sjögren’s syndrome (Gottenberg, Cagnard, Lucchesi, Letourneur, et 
el., 2006). Evidence of this association is the presence of auto-antibodies in the serum of patients 
treated by interferon, development of an autoimmune disease, or the exacerbation of an existing 
one in those patients (Gota and Calabrese, 2003). IFNs contribute to the breakdown of central 
tolerance to the body’s tissue, leading to stimulation of an immune or autoimmune response, a 
sequence that might occur in the inner ear. 
2.2.3.3 Interferons as antiproliferative agents 
 The antiproliferative effect of IFNs is mainly due to their ability to induce programmed 
cell death or apoptosis. Apoptotic responses have been reported in response to both type I (IFN-α 
& IFN-β) and type II (IFN-γ) in tumor cell lines and tumor cells. IFN-induced cell death involves 
activation of the extrinsic pathway as well as the mitochondrial (intrinsic) pathway. In particular, 
IFN-α induces Fas expression (extrinsic pathway) in malignant melanoma, leukemia and basal 
cell carcinoma, with subsequent cell death (Fulda and Debatin, 2002; Inaba, Glibetic, Buck, 
Ravindranath, & Kaplan, 2004).  IFN-α also can lead to the release of cytochrome c and the 
activation of caspase-9, with subsequent activation of downstream caspases such as caspase-3, 
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caspase-6, and caspase-7 (intrinsic or mitochondrial pathway of cell death) (Thyrell, Erickson, 
Zhivotovsky, et al., 2002). Both pathways are activated by some ototoxic agents, e.g., cicplatin 
(Devarajan et al., 2002) and aminoglycosides (Li, et al., 1995). 
2.2.4 Side effects of interferon therapy 
Although IFNs have been successful as potent antivirals, immunomodulators and anticancer 
agents, treatment with IFN carries significant risks (Heathcote & Main, 2005). Many side effects 
have been reported with IFN therapy, including flu-like symptoms, depression, and autoimmune 
reactions (Lisker-Melman, Di Bisciglie, Usala, et al., 1992; Marcellin, Pouteau, Benhamou, 
1995; Benelhadj, Marcellin, Castelnau, et al., 1997). Other studies reported hemolytic anemia 
and abnormal coagulation in about 50% of patients treated with IFNs. These side effects are 
thought to be due to autoimmune reactions that lead to the destruction of RBCs and platelets 
(Poynard, Bedossa, Chevallier, et al., 1995; Becker, Winkler, Klingert, et al., 1994; Vial & 
Descotes, 1994).  
The inner ear is a site for adverse reactions of many medications, e.g., aminoglycosides, 
loop diuretics, and cisplatin, which can act by the same mechanisms as IFNs. Therefore, it can be 
hypothesized that the inner ear may have IFN-induced side effects. A considerable number of 
studies have found an association between hearing impairment and IFN therapy. The following 
section will address this association and review the findings of these studies.  
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2.2.5 Effect of type I interferons (IFN-α/β) on hearing 
Studies concerned with the effect of type I-IFNs on the auditory system are inconsistent. A 
considerable number of studies have documented the occurrence of sensorineural hearing loss 
(SNHL) in patients treated with IFN-α (Cadoni, et al., 1998; Elloumi, et al., 2007; Formann, et 
al., 2004; Johnson, et al., 2008; Kanda, et al., 1994; Le, Bader, & Fazili, 2008; Okanoue, et al., 
1996; Piekarska, et al., 2007; Sachar and Polio, 2004; Salkic, et al., 2009; Wong, et al., 2005). 
The incidence of hearing impairment due to IFN-α was reported more frequently in patients with 
hepatitis C than in patients receiving IFN-α for other diseases. The deteriorating effect of IFN-α 
on hearing also was described in patients with chronic hepatitis B (Gorur, Kandemir, Unal et al., 
2003; Tunca, Erbayrak, Aytac, Turkay, 2004). The hearing loss was described as unilateral (in 
most cases) (e.g., Johnson et al., 2008) or bilateral (e.g., Salkic et al, 2009), reversible (Elloumi 
et al, 2007; Gorur, et al., 2003; Kanda et al., 1994) or irreversible (Okanoue, et al., 1996; Sachar 
and Polio, 2004; Wong et al., 2005). The reported cumulative dose that was found to be 
associated with hearing loss due to IFN-α was around 100 million units (Cadoni et al., 1998; 
Gorur, et al., 2003; Kanda, et al., 1995) 
On the contrary, other studies showed no toxic effect of IFN-α on hearing. For example, 
Kaygusuz, et al. (2004) found no effect of IFN-α on the hearing threshold of patients with 
chronic active hepatitis B. The study included 26 subjects treated with IFN-α.2b in a dose of 10 
million units every other day for 6 months. Although the cumulative dose used in their study was 
higher than the cumulative dose that was found to be associated with hearing loss in other 
studies, no hearing loss was noticed in any of those patients. The authors attributed these 
findings to the small number of patients. Nonetheless, few patients complained of tinnitus, which 
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might suggest the presence of subtle hearing impairment. The audiological testing (conventional 
audiometry) used in Kaygusuz et al.’s study is not the most accurate method to detect subtle 
hearing loss. A more precise tool such as otoacoustic emissions might be useful in detecting 
subtle changes in the cochlea in such patients.  
Akyol, et al. (2001) failed to find pathological changes in the organ of Corti of albino 
Swiss mice treated by IFN-α.  The authors used a single dose of IFN, either in the form of 
100,000 or 50,000 units in two groups of albino Swiss mice and compared the findings between 
both groups and a control group (received no IFN). The auditory brainstem response (ABR) 
findings showed a statistically significant shift in the hearing threshold between baseline and 
post-medication in the treatment group. In addition, a pairwise comparison revealed a significant 
difference in the hearing threshold between the groups that received IFN and the control group. 
Microscopic examination of the cochlea of mice treated with IFN revealed atrophy of the lateral 
wall as well as marked cytoplasmic vacuolation of the epithelial cells of the stria vascularis. 
However, no pathological changes were observed in the sensory elements of the organ of Corti 
(outer and inner hair cells). IFN-α may cause reversible biochemical and metabolic changes in 
the cochlea, rather than morphologic abnormalities. This might be consistent with the well-
known reversible course of INF-induced hearing loss in many patients.  
In addition, Akyol et al. (2001) used a single dose of IFN, which might not be enough to 
induce any hair cell damage. Most ototoxic drugs cause hair cell damage as a result of 
cumulative effects of the drug. In addition, if the underlying mechanism of hair cell damage is 
assumed to be of autoimmune origin, as has been suggested by other investigators, this response 
usually needs repeated doses to be elicited (Suzuki, Krug, & Cheng, 1997). Therefore, using a 
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single dose cannot be expected to induce significant damage to the organ of Corti, which 
supports the need for a study that uses repeated doses of IFN to further delineate this issue. 
Nonetheless, there is evidence that IFN-α can be used for treatment of SNHL that might 
be of viral or autoimmune origin.  For example, Kanemaru, et al. (1997) used IFN-α for the 
treatment of idiopathic sudden SNHL that might be due to viral infection. The authors noticed 
that 27 out of 42 patients (64.3%) with idiopathic SNHL showed complete recovery after IFN -α 
in a dose of three million units (IU) per day for 10 days. In addition , they found a significant 
increase in activity of 2̀, 5 ̀ ̀  oligoadenylate synthetase (an enzyme that indicates the antiviral 
effect of IFN) in 24 out of the 27 patients who showed recovery of hearing loss that was on 
average ≥70  dB before the treatment. The authors suggested that IFN-α can be effective as a 
mono-therapy for the treatment of idiopathic SNHL as such as it can replace the steroid therapy. 
The use of IFN-α in the treatment of idiopathic SNHL will be beneficial in patients who have 
limitations of using steroids, e.g., patients with diabetes mellitus. It is worth noting that IFN-α-
induced SNHL was reported at doses higher than 10 million U, which is more than three times 
the therapeutic dose in idiopathic SNHL. This means that the effect of IFN-α on hearing could be 
dose-dependent, while relatively small doses were effective in treatment of SNHL, large doses, 
which are usually used for treatment of viral hepatitis, for example, might cause hearing loss.  
Several mechanisms have been suggested as underlying causes for hearing loss in 
patients treated with IFN (Akyol et al., 2001; Cadoni et al., 1998; Forman et al., 2004; Fuse, 
Hayashi, Oota, Fukase, Asano, et al., 2003; Lorenz et al., 2002; Tunca et al., 2004). Among these 
mechanisms are the direct toxic effect of INF on cochlear cells (Calvet & Gresser, 1979) and 
immune response, including the inflammatory response (Sarraco, Touscoz, Durazzo, et al., 
1990). In addition, impaired platelet function by IFN might lead to hemorrhage or vasculitis with 
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subsequent ischemia of the stria vascularis (hematologic effect) (Poynard, Bedossa, Chevallier, 
et al., 1995).  
The first possible mechanism is the direct toxic effect of IFN-α on the inner ear, which 
might occur through the induction of apoptosis of the cellular components of the cochlea. The 
Fas-FasL apoptosis pathway is the most commonly described pathway in association with IFN- 
induced apoptosis (Choi, Park, Lee, Lim, Shin, et al., 1999; Fulda and Debin, 2002; Inbal, 
Cohen, Polak-Charcon, et al., 1997). There is an increase in FasL expression in the inner ear in 
response to induction of labyrinthitis or following stimulation with IFN-γ, which confirm the 
presence of FasL receptors in the inner ear (Bodmer, Brors, Pak, Keithley, Mullen et al. (2002, 
2003). IFN-α enhances the secretion of IFN-γ. Therefore, it can be argued that IFN-α can lead to 
apoptosis of the cells of the inner ear, either directly by its own apoptotic effect or by enhancing 
the secretion of IFN-γ. IFN-α also can lead to the release of cytochrome c and activation of the 
intrinsic or mitochondrial pathway of cell death (Thyrell et al., 2002), which also occurs in the 
inner ear (Devarajan et al., 2002; Li et al., 1995).  
The immune response (including the inflammatory reaction) is the second mechanism by 
which IFN-α can cause damage to the inner ear. The contribution of IFN-α to the immune 
system, as has been mentioned in a previous section, involves the activation of cells of the 
immune system and/or the increased secretion of other immunomodulatory cytokines e.g., IFN-γ, 
as well as the increased expression of MHC-I. Many studies have documented that the immune 
response contributes to the etiology of a growing number of inner ear disorders (Harris & Sharp, 
1990; Arnold et al., 1987; McCabe, 1979). The evidence of autoimmunity in patients with SNHL 
has been supported by the presence of autoantibodies against different inner ear proteins in the 
sera of those patients (Suzuki, Krug, & Cheng, 1997).  
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In addition, increased infiltration of both CD4+ and CD8+ was observed in patients with 
suspected autoimmune sensorineural hearing loss (ASNHL) (Mayot, Bene, Dron, Perrin, Faure, 
1993). Natural killer and Th1 cells, which are significant components of the immune system, are 
associated with immune-mediated inner ear diseases and Meniere’s disease; the proliferation of 
these two cells is stimulated by IFN-α (Fuse, Hayashi, Oota, Fukase, Asano et al., 2003). This 
cellular infiltration usually results in an inflammatory reaction with concomitant formation of a 
dense extracellular matrix associated with fibrosis (Yamane, Iguchi, Konishi et al., 1995). 
Therefore, the outcome of the immune response could be the degeneration of the organ of Corti, 
stria vascularis, and spiral ganglion neurons (Berrocal & Ramirez-Camacho, 2000).  
It can be speculated that IFN-α can provoke an immune response in the cochlea either 
directly through activation of cells of the immune system or through production of IFN-γ. This 
speculation is supported by many studies (Cadoni, Agostino, Manna, Santis, Fetoni, et al., 2003; 
Cadoni et al., 1998; Ottaviani, Cadoni, Marinelli, Fetoni, De Santis, et al., 1999). For example, 
Ottaviani, et al. (1999) found anti-endothelial cell antibodies in 15 out of 32 (47%) patients who 
had sudden hearing loss and in two out of 14 of the controls (14%). This suggested an 
association between sudden hearing loss and immune-mediated microvascular damage. These 
anti-endothelial cell antibodies react against surface antigens on the endothelial cells of the inner 
ear blood vessels, leading to their damage via a complement-mediated or antibody-dependent 
cellular cytotoxic mechanism. The same effect has been detected in retinal vascular lesions 
during interferon therapy (Guyer, Tiedeman, Yannuzzi, et al., 1993). Therefore, it can be argued 
that interferon therapy can provoke an immune response in the inner ear, resulting in hearing 
impairment. 
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The third possible mechanism of IFN-induced hearing impairment is hemorrhage or 
vasculitis with subsequent ischemia of the stria vascularis. Anemia and thrombocytopenia 
(decreased platelet counts) are among the side effects of IFNs, where they occur in about 50% of 
patients receiving IFN-α (Poynard, et al., 1995). Ogawa & Kanzaki (1994) observed a sudden 
sensorineural hearing loss in some patients who were receiving IFN-α and had aplastic anemia 
and thrombocytopenia. Those patients experienced total unilateral hearing loss accompanied by 
tinnitus, severe vertigo, and nausea. Ischemic disorders in the stria vascularis, which plays an 
important role in the nutrition of the organ of Corti, might result in SNHL. 
In conclusion, IFN-α can affect the cochlear structures either directly by the virtue of its 
immune, inflammatory, and apoptotic effects or indirectly by enhancing the secretion of IFN-γ. 
To date, no clinical data have suggested that IFN-γ has any effect on hearing. However, many 
experimental studies have shown that IFN-γ can affect the cochlear structures. Therefore, the 
following section will review the findings presented in these studies. 
2.2.6 Effect of type II interferon (IFN-γ) on hearing 
Although according to the available literature, hearing loss was not reported with the exogenous 
(therapeutic) use of IFN-γ in the clinical arena, IFN-γ has been studied at the molecular level in 
the inner ear in experimental animals and tissue culture. Indeed, exogenous IFN-γ was found to 
be associated with an increase in ICAM-1 molecules (Pawankar, Tomiyama, Jinnouchi, Ikezono, 
et al., 1998), MHC class II molecules (Gloddek, Bodmer, Brors, Keithley, and Ryan, 2002), and 
Fas-FasL molecules (Bodmer et al., 2003) which reflect inflammatory, immune and apoptotic 
responses, respectively in the inner ear.  
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2.2.6.1. Interferon-γ as an inflammatory modulator in the inner ear 
IFN-γ can be expressed in various parts of the inner ear as a result of induction of an 
antigen with subsequent expression of inflammatory molecules—ICAM-1. For example, 
Pawankar, Tomiyama, Ikezono, Nonaka, Jinnouchi, et al. (2004) found increased expression of 
IFN-γ in different parts of the inner ear of systemically pre-sensitized rats after keyhole limpet 
hemocyanin (KLH) antigen challenge into the endolymphatic sac. The amount and the timing of 
IFN-γ expression were correlated with the expression pattern of the ICAM-1 molecules, with 
subsequent recruitment of inflammatory cells into the inner ear. These adhesion molecules play 
an important role in the cellular interaction during the immune or the inflammatory response 
(Dustin, Singer, Tuck, & springer, 1988). ICAM-1 is strongly expressed in many sites of the 
cochlea after KLH antigen challenge into the endolymphatic sac (Pawankar, et al., 1998). These 
observations demonstrate that antigen challenge into the endolymphatic sac induces IFN-γ 
expression, which can then upregulate (enhance) ICAM-1 expression and induce cell infiltration, 
suggesting that IFN-γ may play a crucial role in inflammatory/immune-mediated inner ear 
diseases.  
2.2.6.2 Interferon-γ as an immune modulator in the inner ear 
 IFN-γ is a potent inducer of major histocompatibility complex class II (MHC-II), which 
has a critical role in initiation of immune responses, where they present the processed antigens to 
lymphocytes for phagocytosis (Cresswell, 1994). For example, Takahashi and Harris (1988) 
indirectly indicated the presence of MHC class II by showing the invasion of the cochlea by 
macrophages, which produce MHC class-II following immune response. The presence of MHC-
II was directly demonstrated in the normal human endolymphatic sac (removed at autopsy) by 
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using immunohistochemical study with anti- MHC-II antibodies (Altermatt, Gebbers, Muller, 
Arnold, & Laissue, 1990). Since MHC molecules are located on the APCs, including 
macrophages and dendritic DCs, this indicates the presence of these cells in the cochlea 
(Tomiyama & Harris, 1987). Dendritic cells (DCs) were found to produce between 200-1000 
times more IFN-α than any other white blood cells, which might indicate the possibility of 
production of IFN-α in the cochlea. 
In addition, Gloddek et al. (2002) used fluoresce-activated cell sorter (FACS) to study the 
effect of induction of sterile labyrinthitis and repeated doses of IFN-γ on the inner ear structures. 
They found significant increase in MHC-II molecules in the cochlear explants of the lateral wall, 
organ of Corti, modiolus, and spiral ganglia versus the untreated explants. They concluded that 
MHC-II molecules play an important role during inflammatory and immune responses of the 
cochlea, which might lead to irreversible damage of cochlear structures. Gloddek et al. (2002), in 
light of their findings, attributed the hearing loss associated with IFNs administration to their 
robust immunological effects on many cochlear structures.  
In addition, Lorenz, Solares, William, Sikora, Pelfrey et al. (2002) demonstrated the 
presence of IFN-γ producing T-cells in the peripheral blood of patients with autoimmune SNHL 
versus control subjects whose peripheral blood showed no evidence of IFN-γ-producing T-cells. 
Moreover, by using the enzyme-linked immunospot (ELISPOT), Solares and Tuohy (2005) 
observed an increase of peripheral blood IFN-γ-producing T-lymphocytes in patients with 
autoimmune SNHL. Therefore, they suggested that IFN-γ is involved in the pathogenesis of 
autoimmune SNHL.  
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2.2.6.3. Interferon-γ as an inducer of apoptosis in the inner ear 
Interferon-γ increases the expression of the Fas-FasL complex in the inner ear. For 
example, Bodmer, et al. (2002) used FACS to demonstrate the effect of repeated doses of IFN-γ 
and the induction of immune-mediated labyrinthitis in the inner ear cells. They found an increase 
of Fas-FasL from 3-8% in untreated inner ear cells to 35-53% in those treated with IFN-γ, with 
maximum expression of Fas-FasL in the lateral wall, organ of Corti, and modiolus after 24 hours, 
and in the spiral ganglion after 48 hours. There was also a moderate FasL immunostaining in 
marginal cells of stria vascularis and spiral ganglia, whereas, there was a weak FasL reactivity in 
the supporting cells of the organ of Corti.  
In another study, Bodmer et al. (2003) analyzed the cloned DNA (cDNA) generated from 
unstimulated and IFN-γ-stimulated organ of Corti by using real time Polymerase Chain Reaction 
(PCR). They found no changes in transcription of the gene encoding Fas; however, confocal 
microscopy showed dramatic changes in the distribution of Fas in the cellular components of the 
organ of Corti as a result of IFN-γ-stimulation. The distribution of Fas following IFN-γ-
stimulation was consistent with the recruitment of preformed Fas molecules from intracellular 
compartments, e.g., endoplasmic reticulum into the cytoplasm and the plasma membrane rather 
than its biosynthesis as a consequence of genetic expression. The authors suggested that the 
presence of preformed Fas makes its distribution on the cell membrane more rapid than if it 
resulted from genetic expression. Furthermore, they concluded that expression of Fas on the 
plasma membrane might indicate the involvement of Fas in the protection of the inner ear from 
stress by autoimmune or inflammatory responses. Supporting cells were the cells that have this 
protective role because they showed marked distribution of Fas, in contrast to the hair cells that 
showed no labeling with Fas antibodies. This protective role of Fas also was found in the anterior 
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chamber of the eye (Griffith, Yu, Herndon, Green, & Ferguson, 1996). In addition, mice with 
deficient Fas genes show progressive hearing loss. This hearing loss may be due to 
autoimmunity because it was associated with progressive accumulation of autoreactive T-
lymphocytes, degeneration of stria vascularis cells, and progressive endolymphatic hydrops 
(Trune, Craven, Morton & Mitchell, 1989; Ruckenstein, Keithley, Bennett, Powell, Baird & 
Harris, 1999). This reaction means that absence of Fas makes the inner ear more vulnerable to 
the immune response. However, the increased expression of Fas has been observed in cochlear 
cell culture exposed to cisplatin, which is known for its ototoxicity (Van de Water, Nguyen, 
Shoemaker, Schipor, et al., 2001). Therefore, the Fas-FasL complex may participate in the 
protection of cochlear hair cells or it may play an important role in inner ear pathology (Bodmer 
et al., 2003). IFN-γ, which increases Fas expression, can be in turn protective or pathologic to the 
cochlea. Further investigations are needed to delineate this suggestion. Table 1 summarizes the 
studies concerned with the effect of IFN-α/β and IFN-γ on hearing. 
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Table 1: Summary of the studies concerned with IFN and hearing 
Reference 
 
Type of IFNs     Type of study              Findings/comments 
 
Kanda & Shigeno,(1994) 
 
IFN-α or IFN-β 
 
Prospective (Hepatitis C&B) 
 
   HL was more with IFN-β than IFN- α..  
 
Kanda et al. (1995) IFN-α or IFN-β Prospective (Hepatitis C&B)    No difference between the effect of IFN-  
  α or IFN-β on hearing. 
Cadoni et al(1998) IFN-α  Case study    Anti-endothelial cells antibodies detected in 
   the patient’s  serum. 
Okanoue, et al. (1996)  IFN-α Retrospective (Hepatitis C)    Irreversible SNHL in one patient out of 677 
Kanemaru, et al. (1997) 
 
IFN-α Prospective    IFN-α was used in the treatment of idiopathic 
   SNHL. 
Akyol, et al. (2001) 
 
IFN-α Experimental on mouse cochlea    There was a significant rise in hearing 
   thresholds in the IFN-treated  groups by 
   ABR. Histologically, there were a decreased 
   number of fibroblasts in the spiral limbus, with 
   cytoplasmic vacuolation No loss of hair cells. 
Görür, et al. (2003) IFN-α Prospective on Hepatitis B patients    IFN-α in patients with hepatitis B may cause 
   mild reversible SNHL. 
Formann et al.(2004) IFN-α Retrospective of 4 patients    Irreversible SNHL. 
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Reference 
 
Type of IFNs     Type of study              Findings/comments 
Sachar and Polio (2004) 
 
           IFN-α             Case study    Reversible SNHL. 
Wong et al. (2005) IFN-α Case study    Irreversible unilateral severe SNHL.  
Elloumi et al.(2007) IFN-α Case study    Reversible SNHL. 
Piekarska et al. (2007) 
 
IFN-α Case report    Irreversible bilateral SNHL in a  27-     
   year-old patient  with Turner syndrome . 
Johnson et al. (2008) IFN-α Case report    Irreversible severe SNHL, tinnitus and 
   Vertigo. 
Atug, et al. (2009) IFN-α Case report in patient with     
chronic hepatitis C 
   Unilateral reversible SNHL. 
Le, Bader, Fazili. (2009) 
 
IFN-α Case report patient with 
chronic hepatitis C 
   Unilateral SNHL, Prednisone while 
   maintaining  IFN-α. 
Salkic et al. (2009) IFN-α Case report in patient with 
chronic 
hepatitis C 
   Reversible SNHL. 
Bodmer, et al. (2002)           IFN-γ              Experimental  animals 
            IFN-γ and the induction of 
            sterile labyrinthitis 
    Expression of Fas-FasL in the lateral 
    wall, organ of Corti, and modiolus, and the 
    spiral ganglia. 
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Reference 
 
Type of IFNs     Type of study              Findings/comments 
Gloddek et al. (2002) IFN-γ Experimental animals 
Induction of sterile labyrinthitis and 
repeated doses of IFN-γ  
Increase in MHC- II molecules in the cochlear 
explants of the lateral wall, organ of Corti, 
modiolus, and spiral ganglia. 
Pawankar et al. (2004) IFN-γ Experimental animals systemically 
pre-sensitized rats after KLH antigen 
into the endolymphatic sac. 
IFN-γ in different parts of the inner ear was 
associated with the expression of ICAM1. 
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2.3 SUMMARY OF THE LITERATURE REVIEW 
In summary, data concerning the effect of IFNs is inconsistent with a wide range of 
variability; whereas some studies documented their pathological effects on the inner ear, others 
documented their therapeutic usefulness in management of SNHL. Different mechanisms were 
suggested for the effect of both IFN-α/β and IFN-γ. The first mechanism is the direct toxic effect 
on the cellular components of the cochlea that lead to cell death as has been reported with 
different ototoxic agents, such as aminoglycosides and cicplatin. The immune response—
including the inflammatory reaction—is the second mechanism by which both IFNs can affect 
the inner ear. The third mechanism is the hematological effect with the resultant hemorrhage and 
vasculitis of the stria vascularis (Stria vascularis will not be included in the cochlear cell line 
used in the current study). Ultimately, the outcome of these different mechanisms (i.e., 
inflammatory, immunologic, or hematologic) can be assumed to be programmed cell death of the 
cochlear structure. Therefore, IFN-α can lead to apoptosis of the cochlear cells either directly or 
through provoking an immune and/or inflammatory response. This conclusion can be supported 
by the following evidence: 
- Various reports have shown that an autoimmune response, either cell-mediated (produced 
by T-lymphocytes) or antibody-mediated (induced by B-lymphocytes), results in 
enhancement of the Fas expression with subsequent cell death of the target cells (Ju, Cui, 
Panka, Ettinger, and Marshak-Rothstein, 1994). These findings mean that if IFNs initiate 
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an immune response in the inner ear, apoptosis of the inner ear cells can be assumed to be 
the result of this immune response.  
- The ability of Fas itself to induce cell death and its involvement in the IFN-induced 
apoptosis suggests that IFNs can cause Fas-FasL-induced apoptosis of the cochlear 
structures through the extrinsic pathway.  
- Moreover, activation of the STAT1, or interferon regulatory factor 3 (IRF-3) (both are 
included in the IFN signaling pathway), is associated with nitric oxide (NO) and reactive 
oxygen species (ROS) production, with subsequent apoptosis. The production of ROS is 
the underlying mechanism of aminoglycosides (Priuska and Schacht, 1995) and cisplatin-
induced apoptosis (Kopke, Liu, Gabaizadeh, Jacono, Feghali, Spray, et al., 1997). 
Therefore, activation of STAT1 by IFNs might lead to increased production of NO and 
ROS, with subsequent apoptosis of the cochlear cells by the intrinsic pathway of cell 
death. 
- Furthermore, as it has been mentioned in a previous section of the current review, the 
inflammatory and/or the immune response will result in cell death, either by necrosis or 
apoptosis. Mixed necrotic and apoptotic cell death can be found as the pathogenesis of 
the same disease. Some evidence supports that different types of cell death can share 
common mechanisms (Clarke, 1990; Demarchi, Bertoli, Copetti, Tanida, Brancolini, 
Eskelinen, et al., 2006; Yasuhara, Asai, Sahani, Martyn, 2007). 
Figure 2.7 summarizes the effects of both IFN-α (directly or indirectly) through increasing of 
IFN- β and/or IFN- γ on the inner ear structures and shows a theoretical outcome for these 
effects, which is cell death, apoptosis/ necrosis.  
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Figure 7: Schematic diagram showing the predicted effect of IFN on the cochlea 
MHCI/II= major histocompatibility class I/II.   
ICAM1= Intercellular adhesive molecules.       ↑ = increase level. → = result in  
Effect of IFN-γ on the inner 
ear 
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2.4 SIGNIFICANCE AND GOALS OF THE PRESENT STUDY 
The current study is designed to address the following unresolved issues with regard to 
the effect of IFN-α on the auditory system. 
First, clinical findings have suggested an association between hearing loss and IFN-α 
therapy; yet, the underlying mechanism of this association is still unclear. Despite increasing 
evidence for the association of hearing loss with IFN-α, the only experimental study exploring 
this association, to date is that of Akyol, et al. (2001). The authors investigated the effect of IFN- 
α, using audiological and histological approaches which might not be the most accurate 
approaches to precisely rule out the influence of IFN-α on the inner ear—an effect that can be 
determined more precisely at the molecular level. Therefore, there is a need for a study that can 
explore the effect of IFN-α on the inner ear at a molecular or genetic level. 
Second, from a clinical point of view, because IFNs are widely used today in the clinical 
arena, it is important to ensure the safety of such medications to reduce any subsequent handicap 
(in this case, hearing impairment). Regular monitoring of the hearing function might be required 
in those patients, who are receiving IFNs, but the underlying mechanism first must be explored; 
otherwise the particular monitoring used might be misguided. Most of the clinical studies 
concerned with the effect IFN-α has on hearing are retrospective studies; no prior hearing 
evaluation was obtained before IFN-α therapy. 
Third, and in general, understanding the molecular and cellular signals that regulate and 
control the effect of IFNs on the cochlear structures will help in understanding the origin and 
mechanism of many inner ear diseases, especially that of autoimmune origin. This knowledge 
might lead to developing effective methods for preventing unwanted side effects on the inner ear 
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and opening an avenue for new therapeutic agents to manage many inner ear disorders. In 
addition, these findings help in identifying novel diagnostic markers for susceptibility, severity, 
and outcomes of any cochlear pathology. 
To possibly delineate these issues, the current study was designed  to accomplish two 
main goals. The first goal was to investigate if  the cochlea has receptors for IFN-α  and if IFN-α  
would exert its effect directly through stimulation of these receptors or indirectly through the 
enhanceing of the expression of other members of type I-IFN (e.g. IFN-β) or type II-IFN (IFN-
γ). The second goal was to determine the mechanism by which IFN-α  can affect the cochlear 
structures, and if these mechanisms can affect the viability of the cochlear cells. The first goal 
was achieved by examining the expression of IFN-α1, IFN-β, and IFN-γ. The second goal was 
achieved by examining the expression of those genes that might be involved in the induction of 
inflammatory response (ICAM1 and TNF-α), immune response (MHC-1), and apoptosis (Fas 
gene, Caspase-3, and Bax genes). In particular, the following research questions will be 
addressed:  
1- Does the cochlea have receptors for IFN-α? 
2- Does IFN-α act directly on the cochlear cells or by induction of the expression of IFN-γ 
and/or IFN-β in the cochlear cell line? 
3- Does IFN-α induce expression of inflammatory markers, markers for immune response 
and/or markers for apoptosis? 
4- Does IFN-α affect cell viabiliy (cell count) in the cochlear cell culture? 
5- Are the effects of  IFN-α dose and/ or time dependent? 
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3.0  CHAPTER III: METHODOLOGY 
3.1 EXPERIMENT-1 
3.1.1 Experimental Design 
To accomplish the stated goals, a cochlear hair cell line called HEI-OC1 (House Ear 
Institute, Los Angeles, CA) was used as an in-vitro system to examine the molecular events 
associated with treatment of the organ of Corti cells with IFN-α. The cells obtained from the 
culture were treated with IFN-α in three different doses (20, 40, and 80 units/ml of culture 
media) to test if the effect of IFN- α is dose dependent. The dose was calculated according to the 
antiviral assay of IFN-α (Familletti, Rubinstein, and Pestka, 1981). In this assay, a dose of one 
unit/ml IFN-α was found to produce a cytopathic effect of 50% as antiviral. Because in viral 
challenge, the cells are more vulnerable to the effect of IFN than unaffected cells as the case in 
the current experiment, 20U was used as an initial dose.  
Because different mechanisms might be involved in the effect of IFN-α on the inner ear 
(the inflammatory, the immune reaction, and apoptosis) and these mechanisms can occur 
simultaneously or at different periods of treatment with IFN-α, five time points were used to 
assess cell counts and gene expression. These time points included 3, 6, 12, 24, and 48 hours. 
Therefore, the cells resulting from the culture were seeded in the density of 5x104 per well 
 45 
 
containing 2 ml of complete medium, using 5 flat-bottomed 12-well plates, with a total of 60 
wells. The 60 wells were divided into five groups according to the number of hours. They 
corresponded to 3-hour, 6-hour, 12-hour, 24-hour, and 48-hour treatment periods, respectively. 
Each of the five groups was divided into three subgroups according to the dose of IFN-α, 
namely, IFN20 for a relatively small dose (20U/ml), IFN40 (40U/ml), and IFN80 for a relatively 
large dose of IFN-α (80U/ml). In addition, a fourth subgroup represented a control group (IFN0) 
that was treated with phosphate buffered saline (PBS) containing 0.1% bovine serum albumin 
(BSA) in a dose of 80µL/ml. The PBS was used to dilute IFN-α to obtain a concentration of 
10U/µL. This means that the control group received the same buffer solution, but without IFN-α. 
Each of these subgroups was included in three wells (triplicate) to increase the number of the 
experimental units and the power of the statistical test. Summary of the experimental design is 
shown in Table 2. After treatment with IFN-α or PBS (control), the cells from each well were 
collected and counted. Then, the cells were subjected to RNA extraction. Afterward, reverse 
transcription and real time polymerase chain reaction (RT-rt-PCR) were used to examine the 
expression of three sets of genes.  
3.1.1.1 Sets of the genes that were examined in the current study  
The three sets of genes included genes that are specifically expressed by HEI-OC1; the second 
set included those genes that might be triggered by IFN-α (IFN-α-induced genes); and the third 
set included a reference gene. 
Specific genes to the HEI-OC1:  These included the following: 
- Myosin 7a is a marker for outer hair cells (Hasson & Mooseker, 1996). 
- Nestin is a marker for stem-like cells (Lendahl, Zimmerman, McKay, 1990).  
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- Connexin26 is a marker for supporting cells (Lautermann, ten Cate, Altenhoff, et al., 
1998).  
- Calbindin2 is a marker for sensory cells (Slepecky & Ulfendahl, 1993). 
 
 
 
Table 2: Summary of the experimental design (Experiment-1) 
 
       
      Hours 
 
      Dose 
 
3 hours  
 
 
6 hours 
 
 
12 hours 
 
 
 24 hours  
      
 48 hours  
  
Total # of wells 
20U/ml 
# of wells 
IFN20/3 IFN20/6 IFN20/12 IFN20/24 IFN20/48  
3 3 3 3 3 15 wells 
40U/ml 
# of wells 
IFN40/3 IFN40/6 IFN40/12 IFN40/24 IFN40/48  
3 3 3 3 3 15 wells 
80U/ml 
# of wells 
IFN80/3 IFN80/6 IFN80/12 IFN80/24 IFN80/48  
3 3 3 3 3 15 wells 
 Control 
# of wells 
IFN0/3 IFN0/6 IFN0/12 IFN0/24 IFN0/48  
3 3 3 3 3 15 wells 
Total 12 12 12 12 12 60 wells 
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Genes or markers for IFN-α treatment: These include the following genes: 
i. IFN-α gene was examined to verify the presence of IFN-α receptors in the cochlea. 
ii. IFN-β gene was examined because it is expected to be expressed by IFN-α. 
iii. IFN-γ gene was examined because its secretion is expected to be increased by IFN- α. 
iv. ICAM-1 was examined as an inflammatory marker of IFN-α in the cochlear cells.  
v. TNF-α gene was examined as an inflammatory marker for IFN-α. 
vi. H2K1 gene that encodes MHC-1 molecules was examined as a marker for the immune 
response of IFN-α.  
vii. Fas gene was examined as a marker for the extrinsic pathway of apoptosis. 
viii. Caspase-3 was examined as evidence of apoptosis. 
ix. Bax gene was examined as a marker for the intrinsic pathway of apoptosis. 
Reference gene: The 18S rRNA gene was used as a reference to measure the expression of IFN-
α-induced genes. The 18S is a housekeeping gene that is present in all nucleated cells and it is 
necessary for basic cell functions. The mRNA of the housekeeping gene is stable and would not 
be changed by experimental treatments (Foss, Baarsch, & Murtaugh, 1998; Marten, Burke, 
Hayden, & Straus, 1994; Thellin, Zorzi, Lakaye, De Borman, Coumans, Hennen,et al., 1999).  
Since the current experiment involved the cochlear cell line as an in-vitro tool to study 
the effect of IFN-α on the cochlear cells, using rt-PCR, the following section provides an 
overview for both of them. 
3.1.1.2. The cochlear cell lines 
For the present study, a HEI-OC1 cell line was used. This cell line was obtained as a gift 
from Dr. Federico Kalince (House Ear Institute, Los Angeles, CA) and was derived from the 
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organ of Corti of 7 days postnatal transgenic mice (Immortomouse H-2Kb-tsA58, Charles Rivers 
Laboratories, Willmington, MA, USA). Because the organ of Corti cells do not proliferate, 
Immortomouse was used to facilitate the establishment of the cell lines. Most cells in this animal 
harbor a temperature sensitive oncogene (tsA58), a mutant of the SV40 T antigen (Tag) gene (Jat 
and Sharp, 1989). This oncogene is regulated by the MHC-I promoter that can be induced by 
IFN-γ. Under permissive conditions (33°C, and IFN-γ), this gene will be expressed and the cells 
will proliferate; whereas, under non-permissive conditions (39°C and no IFN-γ), proliferation 
will stop and the cells start to differentiate.  
This cell line was obtained as follows (Kalince, Webster, Lim, & Kalince, 2003; 
Devarajan, Savoca, Castaneda, Park, Esteban-Cruciani, 2002; Rivolta & Holley, 2002; Bertolaso, 
Martinin, Bindini, Lanzoni, Parmeggiani et al., 2001; Kalince, Kalince, Boukhvalova, & Kachar, 
1999). Cochlear half turns from the Immortomice were cultured on uncoated plastic culture 
dishes under permissive conditions (33°C, 50 U/ml IFN-γ, and 10% CO2). The Culture contains 
a high glucose Dulbecco’s Eagle medium (DMEM) (Gibco BRL, Gaitherburgh, MD., USA) and 
10% fetal bovine serum (FBS; Gibco BRL). Afterward, the cultures were moved to non-
permissive conditions (39°C and no IFN-γ, and 5% CO2), where cellular proliferation stopped 
and cellular differentiation began. The culture remained under these conditions for up to 180 
days and was monitored by phase contrast and video microscopy. No antibodies were added to 
the culture. Between the outer sulcus and the inner sulcus, where the cells of the organ of Corti 
were expected to grow, clusters of newly generated, epithelial-like rounded cells appeared and 
then coalesced together to form a belt at the boundary with the original explant (Figure 4). 
Afterward, the culture was incubated for 2-5 minutes with trypsin-EDTA (0.25% trypsin, 1 mM 
EDTA; Gibco BRL) to detach the cells from the culture media. Later, the cells were isolated by 
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lifting them using a micropipette and seeded in new culture dishes.  Different cell lines were 
established and cloned including, OC-K1, OC-K2, OC-K3, and OC-K4. They were collected and 
cloned using the limiting dilution method.  
The use of hair cell lines will help to overcome the limitations imposed by using human 
or animal subjects. First, using human subjects to study the effect of IFNs will be limited by the 
frequent use of adjuvant agents with IFN-α, e.g., ribavirin in treatment of hepatitis C and 
fluorouracil in hepatocellular carcinoma (Heathcote & Main, 2005). Their effects on hearing 
should be excluded (Urabe, Kaneko, Matsushita, Unoura, Kobayashi, 1998). A second limitation 
of using human subjects to study the effect of IFN on the auditory system is the comorbidity of 
other diseases that might themselves have a detrimental effect on the auditory system. A third 
limitation (probably, the most important one) is studying the biological effect of IFN-α at a 
molecular and genetic levels will be difficult in human subjects. Although these previous 
limitation imposed by human subjects can be avoided by using an animal model, the high 
expense of animal care, the small amount of tissue available from the animal, as well as the 
pharmacokinetics of the drug make the use of animal models difficult. Moreover, and most 
importantly, using cell lines enables in-depth molecular studies for signaling pathways to be 
performed with no limitations on sample size (Bertolaso et. al., 2001). In particular, the HEI-
OC1 line, derived from these cells expresses several markers that are characteristic of the 
sensory cells of the organ of Corti, such as, calbindin, brain-derived neurotrophic factor, 
calmodulin, connexin 26, organ of Corti protein 2, Math1 and myosin VIIa (OHC) (Rivolta, 
Grix, Lawlor, Ashmore, Jagger, & Holley, 1998). In addition, many studies indicated that HEI-
OC1 cells are five-fold more vulnerable to apoptosis resulting from aminoglycosides than cells 
originating from fibroblasts (Kalince, Lim, & Kalince, 2002). 
 50 
 
 
 
Figure 8: Preparation of the cochlear cell line 
A) Morphology of a cochlear explant cultured for 28 days. Note the ‘ridge’ between the 
multilayered region of the original explant and the monolayer of cells growing in the periphery 
(arrows). B) Higher magnification of the ‘ridge’ area with the focal plane on the top of the 
multilayered cell region (note that the monolayer of cells is out of focus). Cylindrical cells with 
projections resembling Deiters' phalangeal processes (arrow) start to develop after 40 days under 
nonpermissive conditions (39°C). C) The cells in the monolayer, at the boundary with the 
original explant, display a very homogeneous phenotype (arrow). (From Kalinec, et al., 2003) 
 51 
 
Therefore, HEI-OC1 might be the most suitable cell line to study the effects of IFNs on the organ 
of Corti cells in the present study.  
3.1.1.3. Polymerase chain reaction 
Polymerase chain reaction (PCR) is an in-vitro technique of nucleic acid formation, by 
which a particular segment of the DNA molecule can be replicated and amplified. The technique 
includes amplification of two oligonucleotide primers that flank the DNA molecules in question 
by repeated cycles of heat denaturation to separate double-strand DNA (dsDNA) into single 
strands (ssDNA), annealing the primers to their complementary sequences, and extending the 
annealed primers with a heat-stable DNA polymerase. Afterward, PCR data are automatically 
collected and analyzed by computer software to calculate relative gene expression between 
several samples based on a standard curve. This technique is very useful to amplify DNA; 
however, to study gene expression, messenger RNA (mRNA) which is carrying the genetic 
information transcript from the gene is the one that needs to be amplified. The messenger RNA 
is formed as a Xerox for the DNA that carries the gene in question, but it is different from DNA 
in being a single helix, rather than double helix. Because PCR is designed to amplify DNA, the 
mRNA must first be reversely transcribed to DNA by an enzyme known as a reverse 
transcriptase, using a technique called reverse transcription (RT).  
Many studies suggest that real time PCR (rt-PCR) can be used for analysis of limited 
quantities of tissue and may show promise for further qualitative and quantitative studies on the 
molecular mechanisms of hair cell transduction and regeneration (Lee and Cotanche, 1995).  
Therefore, rt-PCR is considered the method of choice for simultaneous detection, amplification 
and quantifying changes in gene expression in a minute number of cells (for example, cochlear 
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tissue) over time (Kubista, Andrade, Bengtsson, Forootan, Jonák, et al., 2006). This method 
provides a very powerful inexpensive and sensitive approach to reveal differentially expressed 
genes.  
In the current study, rt-PCR was used to reveal time and dose-dependent changes of the 
target genes in the hair cell culture challenged by IFN-α.  In particular rt-PCR was used to 
measure the magnitude of expression, if any, of some genes that might be stimulated by IFN-α. 
Analysis of PCR data 
The PCR has three phases, exponential phase, linear phase and plateau phase. The 
exponential phase is the earliest phase and during which, the PCR product increases 
exponentially since the reagents are available in large amounts. The linear phase is characterized 
by a linear increase of PCR product because the PCR reagents start to be limited. In the plateau 
phase, the PCR product reaches plateau because some of the reagents start to be depleted. During 
the exponential phase, the PCR product will double during each cycle if the amplification 
efficiency is close to 100%, which can be achieved by optimizing the PCR conditions, primer 
characteristics, template purity and amplicon length (the length of the product molecule).   
The rt-PCR system is based on the detection and quantitation of a fluorescent reporter, 
(fluorescent dye that binds specifically to the minor groove in ds-DNA), the signal of which 
increases in direct proportion to the amount of PCR product in a reaction (the amplified DNA). 
By recording the amount of fluorescence emission at each cycle, it is possible to monitor the 
PCR reaction during exponential phase where the first significant increase in the amount of PCR 
product correlates to the initial amount of target template (amplicon). The cycle at which this 
significant increase in the target amplicon occurs is called cycle threshold (Ct). The higher the 
starting copy number of the target cDNA, the sooner a significant increase in fluorescence is 
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observed, and the lower the Ct number (i.e., Ct is inversely correlated to the logarithm of the 
initial copy number of cDNA). The level of gene expression is revealed by the ΔCt, where the 
ΔCt represents the Ct of the target gene normalized to the 18S rRNA gene (ΔCt= Ct18SrRNA – Ct 
target). Therefore, ΔCt is the statistic that determines the gene expression, and hence it is the 
statistic of interest in the current study.  
In most experiments, rt-PCR data are quantified relatively by comparing the expression 
of a target gene to the expression of a reference gene (18S rRNA gene was used in the present 
study) and the expression of the same gene (gene in question or target gene) in treatment samples 
and control samples (Pfaffl, 2001). The experiments include treatment samples and control 
samples; for each sample, target genes and a reference gene are included. The goal is to 
statistically test for differences between target and reference genes in treatment samples versus 
control samples. Therefore, the null hypothesis is: the Ct differences between target and 
reference genes will be the same in treatment samples versus control samples. Yuan, Reed, Chen, 
and Stewart (2006) suggested four methods for statistical analysis of PCR data: multiple 
regression model, analysis of covariance (ANCOVA), T-test and Wilcoxon two-group test (non-
parametric test). The authors found that the four methods led to similar results. Therefore, first, 
ΔCt is calculated (=Cttarget− Ct18SrRNA); and then, one of these statistical tests should be 
performed on the ΔCt of various treatment conditions (e.g., doses or hours).  
In addition, relative quantification of the mRNA expression levels of target genes is 
calculated by fold change, which reflects how many folds the amplicon has been changed. This 
fold change can be calculated by using two mathematical models, namely, the efficiency 
calibrated method (Pfaffl, 2001) and the ΔΔCt model (Livak & Schmittgen, 2001); both methods 
are similar. In the current study, the ΔΔCt model was used by calculating ΔCt for the target gene 
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in the control sample and the ΔCt for the target gene in the IFN-treated sample, followed by 
calculation of ΔΔCt: 
ΔΔCt = (Ct18SrRNA – Ct target)A− (Ct18SrRNA − Cttarget)B,  
where A and B are the treatment and control samples respectively (Schmittgen and Zakrajsek,  
 
2002).  
 
Fold change= 2 ΔΔCt 
Therefore, in the current study, two variables from the PCR data were obtained; first was 
the ΔCt, on which the statistical testing was done; the second was the fold change, by which the 
amount of the gene expression was quantified. More than two-fold change in the PCR product 
was assumed to reflect a reliable expression of the gene in question (Proudnikov, Yuferov, 
LaForge, Ann Ho and Kreek, 2003).  
The following sections present the materials that were used and the procedures that were 
followed in this experiment. 
3.1.2 Materials 
The following materials were used in the current experiment: 
3.1.2.1 Cell culture 
HEI-OC1 cell was obtained as a gift from Dr. Federico Kalince (House Ear Institute, Los 
Angeles, CA). The cell line was cultured on uncoated plastic culture dishes, using Dulbecco’s 
modified Eagle medium (DMEM). 
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3.1.2.2. Drugs and reagents  
The following drugs and reagents were used to run the current experiment: 
- Recombinant mouse interferon-α was used in the present study because IFNs are species 
specific with regard to their biological effects (Uze, Lutfalla, & Gresse, 1990).  
- Dulbecco’s modified Eagle medium (DMEM) and fetal bovine serum (FBS) was used for 
cell culture. 
- Trypsin-EDTA was used to detach the adherent cells from the bottom of tissue culture 
plate. 
- Trypan blue stain was used to count the cells and to estimate cell viability. 
- RNeasy Mini Kit for RNA extraction. 
- TaqMan Reverse transcription reagents for reverse transcription. 
3.1.2.3 Real time PCR kit  
For the present study, SYBR Green was used for RT- PCR. The kit contains sufficient 
reagents to perform 200 50-μL reactions. The reaction contains SYBR Green I Dye, AmpliTaq 
Gold® DNA Polymerase, dNTPs, Passive Reference, and optimized buffer components.  During 
the reaction SYBR Green dye binds to double strands DNA (dsDNA), and upon excitation emits 
light. Therefore, as the amount of PCR products increases, fluorescence increases. 
3.1.2.4 Primers 
Gene-specific primers were designed using OLIGO Primer Analysis Software (v6.3, 
Molecular Biology Insights, Inc., Cascade, CO). The following primers were designed 
(Appendix B): 
Primers for hair cell markers: these included the following: 
i. Primer for Myosin-VIIa gene. 
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ii. Primer for Nestin gene. 
iii. Primer for connexin26 gene Forward r 
iv. Primer for Calbindin2 gener 
Primers for IFN-α-induced genes 
i. Primer for IFN-α1 gene.  
ii. Primer for IFN-β gene.  
iii. Primer for IFN-γ genes.  
iv. Primer for ICAM-1 gene.  
v. Primer for TNF- α gene.  
vi. Primer for H2K1 gene that encodes MHC-1.  
vii. Primer for Fas gene.   
viii. Primer for Caspase-3gene. 
ix. Primer for Bax gene.    
Primer for 18S rRNA gene: The 18S rRNA was used to detect 18S rRNA expression as a house 
keeping gene that would not be changed by any treatment. 
3.1.3 Procedures 
The following procedures were followed to pursue the goals of the current study. 
3.1.3.1 Cell culture 
The HEI-OC1 cell line was cultured on uncoated plastic culture dishes, using DMEM media 
in the presence of 10% CO2, 50 U/ml of recombinant IFN-γ, and 10% fetal bovine serum under 
two conditions, permissive conditions and non permissive conditions. The permissive conditions 
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were in the form of  33°C, 10 % CO2, high-glucose DMEM media, 10% FBS, and 50µ IFN-γ; 
whereas, the non-permissive conditions  included 39°C, 5% CO2, high-glucose DMEM, and 
10%, FBS. The culture was monitored daily for any change in the color or clarity of the medium 
and for the confluence. The change in color or clarity of the media might reflect depletion of the 
supplies or infection; once detected, the media should be changed or the culture is discarded. 
None of these changes were noticed in the current experiment. Otherwise, the medium of the 
culture was changed twice a week. The cells were split when the cells reach near 90-95% 
confluence. The splitting was accomplished as follows: 
- Removal of the old media. 
- Washing the culture twice using PBS. 
- Adding 5ml trypsin-EDTA to dislodge the cells from the bottom of the culture plate. 
- Incubating the mixture for 5 minutes. 
- Adding equal amount of the media and placing the mixture in a centrifuge tube. 
- Place 500 micro liter of the mixture for cell count. 
- Spinning the remaining of the mixture at around 700 rpm for 10 minutes.  
- Removing the supernatant and re-suspending the cells in X amount of media according to 
the number of cells and according to the required concentration of the cells in the new 
plates. 
- Moving the culture into one or more new culture flasks.   
- Incubating the new culture under the same conditions.  
- Splitting and passing the cells was repeated according to the rate of cell growth and the 
number of cells needed for the experiment. 
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3.1.3.2 Cell viability assay:   
Cell viability assay was performed to monitor the growth of the culture and to determine 
the effect of IFN-α on cell growth and cell replications. Cell viability was measured by Trypan 
blue exclusion. This dye does not penetrate healthy cell membrane; however it passes through 
the cell membrane of dead cells. Therefore, viable cells will be unstained, whereas dead cells 
will be stained blue.  Briefly, 50 μL of cell suspension was mixed gently with an equal volume of 
0.4% Trypan blue in a test tube for five minutes at room temperature. Then 10 μl of the mixture 
was placed in a hemocytometer to count the number of viable (unstained) and dead (stained) 
cells. The average number of unstained cells were calculated in each quadrant of the 
hemocytometer, and multiplied by 2 x 105 to find cells/ml. The cell count was averaged across 
the three wells (triplicate) for each subgroup. Cell viability assay was performed during passing 
the cells to new flasks, during seeding the cells into plates and after treatment of the cells with 
different doses of IFN or 0.1% PBS at different time points.  
3.1.3.3. Treatment of the cell culture with IFN-α / PBS 
When the cells in the culture flasks reached approximately 85% confluence, the cells 
were seeded into 12-well culture plates (5x104cells/well); each containing 2ml culture media. 
Five plates were used—each was labeled for the corresponding time points, namely, 3, 6, 12, 24, 
and 48 hours (forming a total of 60 wells). The 12 wells in each plate were labeled corresponding 
to the four treatment groups, namely 20U, 40U/ and 80U/ml of IFN-α, and a control group 
(sham) treated with 80U/ml of PBS. Each treatment group as well as the sham was included in 3 
wells. After treatment with IFN-α, the plates were incubated in 39°C, 5% CO2 for the 
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corresponding period of time. After each particular time, the cells were collected from each well 
and stored in -80C for RNA extraction.   
3.1.3.4 RNA extraction  
Total RNA was extracted from each group of the cells collected from the previous steps, 
using RNeasy Mini Kit (Qiagen). According to manufacture protocol: cells were mixed with 
350µL RLT buffer (for lysis of cells before RNA isolation) and 5mm metal bead and 
homogenized by TissueLyzer (Qiagen, Valencia, CA) to dissolve the sample from other cell 
components, while keeping the integrity of RNA. Then cell lysate was centrifuged for one 
minute and supernatant was transferred to a new tube, leaving the cell pellet in the old tube. The 
supernatant was mixed with 350 µL of ethanol 70% and then centrifuged in RNeasy mini 2mL 
collecting tube. Afterward, the sample was washed with 350 µL RWI solution and centrifuged to 
discard the flow through reuse collecting tube. The sample was treated with DNaseI solution to 
purify the sample from any genomic DNA, followed by washing with RWI. The sample also was 
washed by RPE solution. At this point the sample contained RNA only that was eluted in RNase-
free water to ensure protection of the RNA from any contamination. RNA quality and quantity 
were evaluated by gel electrophoresis on a 1.5% agarose/Tris-Borate-EDTA (TBE) gel using 
ethidium bromide staining and 260/280 absorbance (ABS) ratio in a Beckman DU 600 
Spectrophotometer (Beckman, Fullerton, CA, USA). Optical density-OD quantification method 
was run to measure the total amount of RNA extracted from each sample.  
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3.1.3.5 Reverse transcription 
Reverse transcription (RT) of RNA was performed to convert RNA resulting from the 
previous procedure into recombinant DNA (cDNA), using TaqMan Reverse transcription 
reagents. These reactions included 10.0 μl of 10X PCR TaqMan Gold buffer II (Applied 
Biosystems), 30 μl of 25 mM MgCl2, 4 μl of 25 mM of each dNTP, 5 μl of 100 μM of random 
primers (Gibco BRL), 2 μl of RNasin (40 units; Applied Biosystems), 1.25 μl of Super-Script II 
(250 units; Applied Biosystems) and 5 μl (250 ng) of DNA-free total RNA in a final volume of 
100 μl. The reaction was incubated at 25oC for 10 min, 50oC for 50 min and 85oC for 5 min in a 
2700 Thermocycler (Applied Biosystems Inc., Foster City, CA). 
3.1.3.6 Real time Polymerase chain reaction (rt-PCR)  
Quantitative comparisons of gene expression among different groups with regard to 
different doses of treatment and different time points of treatment were measured by means of rt-
PCR (Schmittgen, Zakrajsek, Mills, Gorn, Singer, & Reed, 2000), using SYBR Green Master 
Mix Kit (Applied Biosystems). The kit contained sufficient reagents to perform 200 50-μL 
reactions. The reaction contained SYBR Green I Dye, AmpliTaq Gold® DNA Polymerase, 
dNTPs, Passive Reference, and optimized buffer components. A PCR reaction of 50 μl included 
5 μl of 10× SYBR PCR buffer, 6 μl of 25 mM MgCl2, 4 μl of each dNTP (a mixture of 2.5 mM 
dATP, dGTP and dCTP, and 5 mM dUTP (dUTP was used instead of dTTP to help in 
minimizing the carried over PCR products), 2.5 μl (5 μM) of each gene-specific primer (forward 
and reverse for all target genes), 0.5 μl of AmpErase UNG (0.5 units), 0.25 μl of AmpliTaq Gold 
(1.25 units) and 5 μl of cDNA (250 ng) in a final volume of 50 µl. All the reagents were kept on 
ice during the set up for the experiment. This mix was placed in a 96-well plate. The plate was 
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sealed, mixed, and spun to remove any air bubbles in the wells. The reaction was submitted to 
the following thermal cycling parameter. 
Incubation in 50 C° for 2 minutes, in 95C° for 12 minutes for Taq Activation, then, 35 cycles at  
95 C° for 15 seconds for DNA denaturation and in 60C° for 1 minutes for annealing and 
extension in ABI PRISM® 7300 Sequence Detection System (SDS) (Applied Biosystems).  
7300 Sequence Detection software (Applied Biosystems) was used for instrument 
control, automated data collection and data analysis. Relative quantification (fold difference) of 
the expression levels of each transcript was calculated using the 2-∆∆Ct method (Schmittgen and 
Zakrajsek, 2002) with modifications (Li-Korotky et al., 2009). The ∆Ct represents the Ct of the 
target gene normalized to 18S rRNA (∆Ct = CtTarget – Ct18S rRNA).  Relative quantification (fold 
change) of the expression level of the target gene was calculated using a modified 2(∆∆Ct) 
method, where ∆∆Ct = (CtTarget – Ct18S rRNA)Target – (CtTarget – Ct18S rRNA)Control.   
3.1.4 Data analysis 
Data were collected and included the following: 
- Fold change for each gene. 
- ΔCt for each gene. 
- Cell count for each treatment group. 
First, the presence or absence of each gene was determined by measuring its fold change. 
More than two-fold increase is considered a reliable indication of change in the expression of the 
gene relative to the control group (sham), which was normalized to the 18S rRNA gene. Because 
calculation of fold changes is considered a quick way to determine the presence or absence of a 
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particular gene, an initial screening was done for some genes to examine if the dose regimen (20, 
40, & 80U/ml) was sufficient to induce expression of any of these genes that were questioned in 
the current study. These genes included ICAM1 and TNF-α as inflammatory genes and caspase-
3 and Bax genes as apoptotic genes. The results of this screening procedure showed that none of 
those genes were expressed in a significant amount (none of them exceeded two- fold increase). 
The results of experiment-1 are depicted in the results section (Chapter IV). Because none of 
these genes were expressed, no further statistical tests were performed on their ΔCt.  
Therefore, another experiment (experiment-2) was run, using relatively higher doses, 
namely 200 and 2000U/ml media. The dose of 200U/ml, which is almost two times the 
maximum dose (80U/ml) used in experiment-1, was chosen to represent a relative increase in the 
previous dose regimen. Most studies on interferons used a wide range of doses starting with one 
unit to 100,000U/ml media. The strategy when the effect of cytokines (receptors ligand) needs to 
be tested on different cell types is to increase the dose by 10 folds, 1, 10, 100, 1000,….100,000. 
According to the available literature, one unit of IFN-a was found to produce 50% cytopathic 
changes in antiviral assay (Familletti,et al., 1981), and based on that, a dose of  20U was chosen 
as an initial dose in the first experiment. Therefore, in the new experiment 200U (10 times of the 
initial dose) and 2000U (10 times of 200U) were used. In addition, only four time points, 
including 6hrs, 12hrs, 24hrs, and 48hrs were used in the second experiment because there was 
not much change in gene expression at 3hrs in Experiment 1. Eliminating this step saved 
laboratory supplies from being wasted by running unnecessary steps.  
The following section presents the experimental design, the materials used as well as the 
procedures followed in experiment-2.    
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3.2 EXPERIMENT- 2 
3.2.1 Experimental design for experiment-2 
The cells resulting from the culture were seeded in the density of 5x104 per well containing 2 ml 
of complete medium, using 4 flat-bottomed 9-well plates, with a total of 36 wells. The 36 wells 
were divided into four groups according to the number of hours. They were labeled as: 6hrs, 
12hrs, 24hrs, and 48hrs.  
Each of the four groups was divided into three subgroups according to the dose of IFN-α 
(table 3), which included: 
- IFN0 acted as a control (sham) group that was treated by 0.1% PBS in a dose of 
2000µL/ml, with no IFN-α. 
- IFN200, which was treated by IFN-α in a dose of 200U/ml media. 
-  IFN2000, which was treated by IFN-α in a dose of 2000U/ml.  
All the other elements of the design were the same as in the first experiment. 
3.2.2 Materials and procedures for experiment-2 
All the materials that were included in experiment-1 also were used in experiment-2. Also, all 
the procedures followed in the experiment-1 were followed in experiment-2 except for the 
treatment procedure, in which the number of wells as well as the number of time points was 
changed (see Table 3 for details). 
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Table 3: Summary of experimental design for experiment-2 
 
      
           
Hours 
Dose 
 
6 hours 
 
 
12 hours 
 
 
24 hours  
 
48 hours  
 
Total # of 
wells 
IFN0 
# of wells 
IFN0/6 IFN0/12 IFN0/24 IFN0/48  
3 3 3 3 12wells 
IFN200 
# of wells 
IFN2000/6 IFN200/12 IFN40/24 IFN200/48  
3 3 3 3 12 wells 
IFN2000 
# of wells 
IFN2000/6 IFN2000/12 IFN2000/24 IFN2000/48  
3 3 3 3 12 wells 
Total 9 9 9 9 36 wells 
     
  
 65 
 
When the cells in the culture flasks reached 85% confluence, the cells were seeded into 9-
well culture plates (5x104cells/well); each well contained 2ml culture media. Four plates were 
used; each plate was labeled for the corresponding time points, namely, 6, 12, 24, and 48hrs. The 
nine wells in each plate were divided into three groups—3 wells each corresponding to the three 
different doses of IFN-α, namely (IFN0, IFN200, and IFN2000). After treatment with IFN, the 
cultures were incubated in 39°C, 5% CO2 for the corresponding period of time. After each 
particular time, the cells were collected from each well and stored in -80C for RNA extraction. 
The IFN0 group was treated with 2000U/ml of PBS forming the control group. 
 
3.2.3 Data analysis for experiment-2 
Data were collected and included the following: 
- Fold change for each gene. 
- ΔCt for each gene. 
- Cell count for each treatment group. 
First, the presence or absence of each gene was determined by measuring its fold change, 
including the genes that are specific to HEI-OC1 and the IFN-α-induced genes.  
The second part of the analysis was to quantitatively determine those genes that were 
expressed in the cochlear cells as a result of IFN-α treatment with respect to dose and time of 
IFN-α treatment, using the ΔCt as the statistic of interest. The ΔCt for each gene was collected 
and then compared across different doses and across different time points. This part of the 
analysis was not applied for the genes that are specific to HEI-OC1, the presence of which would 
validate the presence of viable hair cells in the growing culture used in the current experiment.  
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Also, the cell count from the cell viability assay procedure was averaged across the wells 
included in each subgroup and then compared across different doses and across different time 
points. 
Therefore, there were two independent variables (dose and time) with three and four levels 
respectively and two dependent variables (ΔCt and cell counts), which created a 3X4 factorial 
design for the ΔCt and for the cell count.  
3.2.4 Statistical analysis for experiment-2 
The goal of the first level of data analysis was achieved by calculating the fold-increase for each 
gene; the gene was considered reliably expressed if there was more than two-fold increase in the 
PCR products relative to the control group as well as to the 18S rRNA. The calculation was done 
for those genes that are specific to the cochlear cells as well as for each of IFN-α-induced gene to 
initially determine if these genes were expressed or not. 
The goal of the second level of the analysis was to statistically test for the presence of 
significant effects of both the dose and the time (two independent variables) on the ΔCt of each 
IFN-α-induced gene and on the cell count (two dependent variables). Livake and Schmittgen 
(2001) documented that ΔCt calculation satisfies assumption for the use of parametric statistics 
such as t-test and ANOVA.  Since t-test compares two means—each should be with one level 
only, the alternative to t-test in the case of multiple means with multiple levels would be the 
analysis of variance “ANOVA”.  Therefore, for this experiment, two-way ANOVA was 
performed (four levels of time X three levels of the treatment). In particular, a separate two-way 
ANOVA for each gene and one for cell count (a total of 9 two-way ANOVAs) were performed. 
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Differences will be considered significant when P-value < 0.05 (i.e. alpha=0.05). ANOVA 
testing was applied only for those genes that showed a reliable fold increase (more than two 
folds). 
A post hoc analysis, using the least difference test (LSD) was done to examine for 
significant differences across the three levels of the dose (IFN0, IFN200, and IFN2000); 
likewise, for significant differences among the four time points (6hrs, 12hrs, 24hrs, and 48hrs). 
LSD does not correct for alpha, which is beneficial for the current study as the least difference 
would be sufficient to justify significance for this kind of data.  
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4.0  CHAPTER IV: RESULTS  
4.1 RESULTS OF EXPERIMENT-1 
Fold change was used to determine if the gene was expressed or not. The gene is considered 
expressed if there was two-fold increase in its level relative to the control, which was normalized 
to the 18S rRNA gene. 
Figures 9, 10, 11, 12 and 13 showed the relative fold changes for IFN-γ, TNF-, ICAM1, 
Caspase-3, and Bax genes, respectively. None of these genes showed more than two-fold 
increase, which means that none of them was expressed by such small doses of IFN-α used in 
experiment-1 (20, 40, & 80 U/mL). However, the patterns of the fold change look similar along 
the three doses. Because none of these genes were expressed in a significant amount, there was 
no need to run two-way ANOVA or any further statistical test for any of them.  
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Figure 9: Relative fold changes in IFN-γ gene expression- Experiment-1 
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Figure 10: Relative fold changes in ICAM1 gene expression- experiment-1 
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Figure 11: Relative fold changes in TNF-α gene expression in experiment-1 
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Figure 12: Relative fold changes in caspase-3 gene expression in experiment-1 
 
 
 
 
 
 
 
-1.6
-1.4
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
3hrs 6hrs 12hrs 24hrs 48hrs
Fo
ld
 c
ha
ng
e
Hours
Caspace-3
IFN-a-80
IFNa-40
IFNa-20
Sham-IFNa-0
 73 
 
 
 
 
 
 
 
Figure 13: Relative fold change in BAX gene expression in experiment-1 
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4.2 RESULTS OF EXPERIMENT-2 
First, the fold change was used to determine if the gene was reliably expressed or not. For the 
genes that are specific for the hair cells, only fold change calculation was done to determine the 
presence or absence of these genes. For the IFN-α-induced genes, the results include those from 
the fold change calculation for each gene and the results of the two-way ANOVA followed by 
the results of post hoc analysis, using LSD. The following section will illustrate the details of 
these results.  
4.2.1 Expression of genes specific for hair cells 
- Myosin VIIa: Figure 14 shows the expression of myosin-VIIa gene. There was an 
increase in the fold up to 10 folds, which indicates the presence of myosin-VIIa gene.  
- Connexin26: Figure 15 shows the expression level of connexin gene, which did not 
exceed 2 fold changes, i.e., the hair cells in the cochlear cell line used in the current 
experiment did not express connexin 26 gene.  
- Nestin gene: There was an increase in the expression level of nestin gene that ranged 
from 2-6 folds (Figure 16). 
- Calbinidin2 gene: Figure 17 shows the fold changes in the calabindin2 expression level 
that ranged from 6-13 folds; however, the gene could not be detected at 48 hours. 
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Figure 14: Relative fold changes in Myosin-VIIa gene expression 
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              Figure 15: Relative fold changes in Connexin26 gene expression 
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             Figure 16: Relative fold changes in Nestin gene expression 
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Figure 17: Relative fold changes in Calbidin2 gene expression 
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4.2.2 Expression of IFN-α -induced genes  
Table 4 shows the means and standards deviation for ΔCt of all the IFN-α-induced genes. This 
will be followed by a detailed description of the findings for each gene. 
 
 
 
Table 4: Descriptive Statistics for ΔCt of all IFN-α-induced genes 
 
 
 
    
 
Gene N Minimum 
   
Maximum 
       
Mean STDV 
ΔCT-IFN- α1 36 23.41       29.94     26.1142 1.86281 
ΔCT-IFN-β  36 21.36        28.93     24.7644 2.17972 
 
ΔCT-TNF-α 36 20.33        32.23     25.7675 1.88526 
      
ΔCT-ICAM1 36 16.85        20.42     18.8992 0.93173 
      
ΔCT-MHC1 36 14.66        17.84     16.0106 0.99651 
      
ΔCT-Fas 36 10.51        14.08     12.6733 0.62402 
 
ΔCT-Casp-3 36 10.20        12.67     11.4900 0.66508 
      
ΔCT-Bax 36 8.91        11.84     10.3467 0.65771 
      
 
 80 
 
4.2.2.1 Expression of other types of interferons 
The results showed expression of type I interferon (IFN-α1 and IFN-β); however there was no 
reliable expression of type II interferon (IFN-γ).  
4.2.2.1.1 Expression of IFN-α1gene 
The first research question of the current study was to determine if IFN-α can be expressed in the 
cochlear cells. Figure 18 shows that there was about 2-4 folds increase of IFN-α1 in the case of 
200 U/ml and about 3.5-6 folds increase in the case of 2000U/ml.  
Table 4 shows the output of two-way ANOVA, which revealed a significant effect of the 
dose on the expression of the IFN-α1 (P<.05, P=.000). However, the effect of time in hours was 
not significant (P=0.342>0.05). The interaction between the dose and the time was not 
significant (P=0.916), which means that the effect of dose was independent of the effect of the 
time of treatment. 
Since the dose effect was significant, a post-hoc analysis was done to examine the 
significant difference between all possible pairs of the dose levels, using LSD test (table 5). The 
analysis reflected a significant difference between IFN0 & IFN200, IFN0 & IFN2000, and 
IFN200 & IFN2000 (P=0.000, 0.000, & 0.004 respectively).  
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Figure 18: Relative fold changes in IFN-α1 gene expression 
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Table 5: Output of two-way ANOVA for ΔCt of IFN-α1 gene 
     
       Variable df Mean Square F-value Significance 
       Dose* 2 50.085 69.373 0.000 
      Time 3 0.845 1.170 0.342 
      Dose X time 6 0.237 0.328 0.916 
*: The mean difference is significant at the 0.05 level 
 
 
 
 
Table 6: Post-hoc analysis for the effect of dose on ΔCt for IFN-α gene 
   
Levels of dose Std Error Significance 
IFN0-IFN200*   0.34688      0.000 
IFN0-IFN2000*   0.34688      0.000 
IFN200-IFN2000* 0.34688     0.004 
*: The mean difference is significant at the 0.05 level 
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4.2.2.1.2 Expression of IFN-β gene 
Figure 19 shows that IFN-β was expressed in the cochlear cells. The expression level was higher 
in the case of 2000U/ml (6-11folds) than in the case of 200U/ml of IFN-α (2-5 folds). However, 
the pattern of change across different time points was almost the same for both doses, with the 
highest level of expression was during the 48-hrs-time point. 
Table 7 shows the output of the two-way ANOVA, which revealed a significant effect for 
both the dose and the time on the expression of the β gene (P=0.000 & 0.005 respectively). 
However, the interaction between the dose and the time was not significant (P= 0.855).  
Post-hoc analyses were completed to examine the significant difference of all possible 
pairs between different levels of the dose and different levels of the time, using LSD test (tables 
8 & 9, respectively). The analysis reflected significant difference between all levels of the dose 
(P=0.000, 0.000, & 0.004); however, the hour levels were significant at 6-24 hrs, 12-24 hrs, and 
24-48hrs only (P=0.000, 0.006 & 0.009).  
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Figure 19: Relative fold changes in IFN-β gene expression 
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Table 7: Output of two-way ANOVA for ΔCt of the IFN-β gene  
     
      Variable df Mean Square F-value       Significance 
        Dose*  2 52.786 42.552744 0.000 
        Time*  3 7.835 6.3160129 0.005 
        Dose X time  6 0.595 0.425 0.855 
*: The mean difference is significant at the 0.05 level 
 
 
 
Table 8: Post-hoc analysis for the effect of dose on ΔCt of IFN-β gene 
   
pairwise Std Error Significance 
IFN0-IFN200* 0.34688      0.000 
IFN0-IFN2000*   0.34688       0.000 
IFN200-IFN2000* 0.34688     0.004 
*: The mean difference is significant at the 0.05 level 
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Table 9: Post-hoc analysis for the effect of time on ΔCt IFN-β gene 
   
Levels of time  Std Error Significance 
6-12 hrs       0.52504          0.210 
6-24 hrs*       0.52504          0.000 
6-48 hrs       0.52504          0.169 
12-24 hrs       0.52504          0.006 
12-48 hrs*       0.52504          0.900 
24-48 hrs*       0.52504          0.009 
*: The mean difference is significant at the 0.05 level 
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4.2.2.1.3 Expression of IFN-γ 
Another gene that might be upregulated by IFN-α is IFN-γ gene, which is a macrophage marker. 
The level of the gene expression could not be detected by fold change (Figure 20), which 
indicates that IFN-γ gene was not expressed by IFN-α treatment even in small amounts at the 
highest Ct cycle number used for PCR. Therefore, there was no need to run two-way ANOVA in 
this case. 
 
 
 
 
 
 
Figure 20: Relative fold changes in IFN-γ gene expression in experiment-2 
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4.2.2.2. Expression of inflammatory markers 
The first part of the third research question was to detect if IFN-α induced inflammatory markers 
in the cochlear cell culture. Two inflammatory genes were examined in the present study 
including, ICAM1 gene and the TNF-α gene. 
4.2.2.3.1. Expression of ICAM1 gene  
Figure 21 shows the expression level of ICAM1 gene. There was an increase in the expression 
level of about 2-5 folds for 2000U dose, with less than two fold-change in the case of 200U dose. 
However, the expression level declined during the later hours, reaching its minimum level at 24 
and 48 hours in both cases (both 200& 2000U of IFN-α showed similar pattern of change in 
ICAM1 gene expression). 
In addition, two- way ANOVA was performed to determine if changing the dose and 
time of IFN-α treatment had an effect on ICAM1gene expression. Table 10 shows that changing 
the dose did not have a significant effect on ICAM1 gene expression (P=0.230). On the other 
hand, changing the time had a significant effect on ICAM1gene expression (P=0.000). The 
interaction did not show any significant effect (P=0.386). 
Post-hoc analysis, using LSD (table 11) reflected significant differences of different 
levels of hours, including 6 &12 hrs, 6 & 24hrs, 12 & 24hrs, and 12 & 48 hr (P=0.015, 0.000, 
0.001, & 0.005, respectively). There was no significant difference in the period between 6 hr and 
48 hr- time points (P=0.428).  
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Figure 21: Relative fold changes in ICAM1 gene expression in experiment-2 
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Table 10: Output of Two-way ANOVA for ΔCt of ICAM1gene 
     
Variable df Mean Square F-value        Significance 
Dose 2 0.680 1.563 0.230 
Time * 3 5.232 12.033 0.000 
Dose X time 6 0.482 1.108 0.386 
*: The mean difference is significant at the 0.05 level 
 
 
 
 
Table 11: Post-hoc analysis for the effect of time on ΔCt of ICAM1 gene 
   
Levels of time Std Error Significance 
6-12 hrs* .20369      0.015 
6-24 hrs* .20369      0.000 
6-48 hrs .20369       0.173 
12-24 hrs* .20369       0.001 
12-48 hrs* .20369       0.005 
24-48 hrs .20369       0.232 
*: The mean difference is significant at the 0.05 level 
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4.2.2.3.2 Expression of TNF-α gene  
TNF-α showed about 2-7-fold increase in the case of 2000U and 2-4 folds increase in the case of 
200U. The peak increase was at 12 hours; however the gene expression declined afterward to 
reach its minimum at 48hrs in both doses (Figure 22).  
Two-way ANOVA (Table 12) indicated no significant difference for the effect of dose 
(P=0.722) or the interaction (P=0.316) on the ΔCt of TNF-α. However, the effect of time on ΔCt 
of TNF-α gene was significant (P=0.003).  
A post-hoc analysis (Table 13) reflected significant difference for the effect of IFN-α at 
6-12 hrs, and 6 - 24 hrs (P=0.000 & 0.012 respectively) as well as between 12 hrs and 48 hrs 
(P=0.013).  
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Figure 22: Relative fold changes in TNF-α gene expression in experiment-2 
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Table 12: Output of two-way ANOVA for ΔCt of TNF-α gene 
     
Variable df Mean Square F-value       Significance 
Dose 2  0.816 0.333 0.722 
time* 3 15.191 6.200 0.003 
Dose X time 6 3.065 1.251 0.316 
*: The mean difference is significant at the 0.05 level 
 
 
 
 
Table 13: Post-hoc for the effect of time on ΔCt of TNF-α1 gene 
   
Levels of time    Std Error Significance 
6-12 hrs* 0.740 0.000 
6-24 hrs* 0.740 0.013 
6-48 hrs 0.740 0.168 
12-24 hrs 0.740 0.175 
12-48 hrs* 0.740 0.013 
24-48 hrs 0.740 0.211 
*: The mean difference is significant at the 0.05 level 
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4.2.2.3 Expression of markers for the immune response 
The second part of the third research question was to determine if IFN-α can induce genes that 
might be specific for an immune response; the H2K1 gene that encodes MHC1 was examined for 
this purpose. The result of experiment-2 showed an increase in the MHC1 gene expression by 
about 3 folds in the case of 200U of IFN-α versus 6-8 fold-increases in case of 2000U of IFN-α. 
The pattern of the fold change was similar for both cases (Figure 23).  
In addition, two-way ANOVA indicated significant effects for both dose and time on the 
ΔCt of MHC-I gene, with P= 0.000 and 0.001, respectively (Table 14). 
The results of LSD test indicated significant differences between IFN0 & IFN200, IFN0 
& IFN2000, and IFN200 & IFN2000 (P=0.000, 0.000, and 0.000, respectively) (Table 15). On 
the other hand, Table 16 shows the output of the LSD test indicating significant differences 
between 6 & 24 hrs, 12 & 24 hrs, 24 & 48 hrs time points (P=0.001, 0.029, and 0.000, 
respectively).  
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Figure 23: Relative fold changes of MHC1 gene expression in experiment-2 
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Table 14: Output of two-way ANOVA for ΔCt of MHC-I gene  
     
Variable df Mean Square    F-value Significance 
Dose*   2  15.618    246.631    0.000 
Time*               3  0.464    7.320     0.001 
Dose X hours               6  0.102     1.604     0.189 
*: The mean difference is significant at the 0.05 level 
 
 
 
 
Table 15: Post-hoc analysis for the effect of dose on ΔCt of MHC-I gene 
   
Levels of dose Std Error Significance 
FN0-IFN200*  0.10273          0.000 
IFN0-IFN2000*    0.10273            0.000 
IFN200-IFN2000*  0.10273          0.000 
*: The mean difference is significant at the 0.05 level 
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Table 16: Post-hoc analysis for the effect of time on ΔCt of MHC-I gene 
   
Levels of time Std Error Significance 
6-12 hrs 0.11863 0.116 
6-24 hrs* 0.11863 0.001 
6-48 hrs 0.11863 0.868 
12-24 hrs* 0.11863 0.029 
12-48 hrs 0.11863 0.085 
24-48 hrs* 0.11863 0.000 
*: The mean difference is significant at the 0.05 level 
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4.2.2.4 Expression of markers for apoptosis 
The third part of the third research question was to determine if IFN-α can induce expression of 
markers for apoptosis, which included, Fas gene, Caspase3 gene, and Bax gene. 
4.2.2.4.1. Expression of Fas gene  
Figure 24 shows that the expression level of Fas gene exceeded three-fold increase only at 12 hrs 
in the case of IFN2000; whereas the expression level showed less than two-fold increase at any 
time point in the case of IFN200.  However, the pattern of fold-change was almost similar in 
both cases (peak at 12 hrs and minimum change at 48hrs). 
In addition, two- way ANOVA (Table 17) indicated no significant effect of the dose 
(P=0.127) or the interaction (P=0.592); however, there was significant effect of changing the 
time on Fas gene expression (P=0.002).  
Post-hoc analysis using LSD test (Table 18) indicated significant differences between 6 
& 48 hrs, 12 & 48 hrs, 24 & 48 hrs time points (P=0.001, 0.001, and 0.001, respectively).  
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Figure 24: Relative fold changes in Fas gene expression in experiment-2 
 
 
 
 
 
 
 
-0.5
0
0.5
1
1.5
2
2.5
3
3.5
4
6hrs 12hrs 24hrs 48hrs
Fo
ld
 c
ha
ng
es
Hours
Fas
IFN2000
IFN200
Sham-IFN0
 100 
 
Table 17: Output of two-way ANOVA for ΔCt of Fas gene 
     
Variable df Mean Square   F-value Significance 
Dose 2    0.575   2.250    0.127 
Time* 3    1.715   6.711   0.002 
Dose X Hours 6    0.200   0.782   0.592 
*: The mean difference is significant at the 0.05 level 
 
 
 
 
Table 18: Post-hoc analysis for the effect of time on ΔCt of Fas gene 
   
Levels of time Std Error Significance 
6-12 hrs 0.23832 0.649 
6-24 hrs 0.23832 0.737 
6-48 hrs* 0.23832 0.003 
12-24 hrs 0.23832 0.905 
12-48 hrs* 0.23832 0.001 
24-48 hrs* 0.23832 0.001 
*: The mean difference is significant at the 0.05 level 
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4.2.2.4.2 Expression of caspase-3 gene  
Figure 25 shows the gene expression level of Caspase3. Although the expression level exceeded 
up to three folds in the case of 2000U of IFN-α, there was less than a two-fold increase in the 
case of 200U of IFN-α.  The pattern of gene expression was similar in both cases, showing peaks 
around 12 hrs and maximum decline at 48hrs.  
In addition, two- way ANOVA reflected significant effect of the dose and time on 
caspase-3 gene expression (P=0.048 & 0.007, respectively); whereas no significant effect of the 
interaction (P=0.555) (Table 19). 
Post hoc analysis revealed significant differences between IFN0 & IFN2000 (P=0.017) 
only, no significant differences between IFN0 & IFN200, or IFN200 & IFN2000 (P=0.085, and 
0.450 respectively) (Table 20). Analysis also revealed significant difference between 6-48hrs, 
12-48hrs, and 24-48hrs (P=0.027, 0.001, & 0.005, respectively) only (Table 21). 
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Figure 25: Relative fold changes in Caspase-3 gene expression - experiment-2 
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Table 19: Output of two-way ANOVA for ΔCt of Caspase-3 gene 
     
Variable    df Mean Square F-value     Significance 
Dose*    2     1.039 3.458            0.048 
Time*    3     1.562 5.199            0.007 
Dose * Time    6     0.251 0.836 0.555 
*: The mean difference is significant at the 0.05 level 
 
 
 
Table 20: Post-hoc analysis for the effect of dose on ΔCt of Caspase-3 gene 
Levels of dose Std Error Significance 
 IFN0-IFN200*       0.22378           0.085 
IFN0-IFN2000*         0.22378            0.017 
IFN200-IFN2000*       0.22378          0.450 
*: The mean difference is significant at the 0.05 level 
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Table 21: Post-hoc analysis for the effect of time on ΔCt of Caspase-3 gene 
   
Levels of time Std Error      Significance 
6-12 hrs 0.25839 0.199 
6-24 hrs 0.25839 0.482 
6-48 hrs* 0.25839 0.027 
12-24 hrs 0.25839 0.550 
12-48 hrs* 0.25839 0.001 
24-48 hrs* 0.25839 0.005 
*: The mean difference is significant at the 0.05 level 
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4.2.2.4.3 Expression of Bax gene 
Figure 26 shows less than two-fold increase in the expression of the Bax gene for either dose of 
IFN-α. However, there was a peak, reaching around two folds at 24hrs in the case of 2000U of 
IFN-α. The two- way ANOVA results (Table 22) indicated significant effect of time on ΔCt of 
Bax gene (P=0.000); whereas, the effects of the dose or the interaction between the dose and 
hours were not significant (P=0.138 & 0.172, respectively).  
In addition, LSD test revealed significant differences between 6-24, 6-48hr, 12- 24hr, 12-
48hr, and 24- 48hr time points (P= 0.001, 0.000,0.028, 0.000, & 0.000) (Table 23). 
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Figure 26: Relative fold changes in BAX gene expression - experiment-2 
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Table 22: Output of two-way ANOVA for ΔCt of Bax gene 
     
Variable       df Mean Square   F-value Significance 
 Dose       2      0.202    2.151     0.138 
Time*       3      3.848    40.986     0.000 
Dose X Time       6       0.157     1.668     0.172 
*: The mean difference is significant at the 0.05 level 
 
 
 
 
Table 23: Post-hoc analysis for the effect of time on ΔCt of Bax gene 
   
Levels of time Std Error      Significance 
6-12 hrs 0.14444 0.147 
6-24 hrs* 0.14444 0.001 
6-48 hrs* 0.14444 0.000 
12-24 hrs* 0.14444 0.028 
12-48 hrs* 0.14444 0.000 
24-48 hrs* 0.14444 0.000 
*: The mean difference is significant at the 0.05 level 
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Table 24 summarizes the findings for IFN-α-induced genes examined in the current study 
 
 
 
Table 24: Summary of the findings for IFN-α-induced genes 
    
Gene Fold change ANOVA Indication for 
IFN-200 IFN-2000  Dose Time 
IFN-α 2-4folds 3-6folds Sa N-Sb          IFN-α expression 
IFN-β  2-5folds 4-11folds Sa Sa          other types of IFN 
IFN-γ NDc NDc NA d NAd          No IFN-γ expression 
TNF-α 2-4folds 2-6folds N-Sb Sa          Inflammatory response 
ICAM1 N-Sb 3-4folds N-Sb Sa          Inflammatory response 
MHC-I 3folds 6-8folds Sa Sa          Immune response  
Fas N-Sb 3.5folds Sa N-Sb           Apoptosis 
Caspase-3 N-Sb 2-3 folds Sa Sa          Apoptosis 
Bax N-Sb 2folds N-Sb Sa          Apoptosis 
a: S= significant       b: N-S= not significant     
b: ND= not detected   d: NA=not-applicable 
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4.2.3 Effect of IFN-α on cell count of the cell culture 
The fourth research question examined if IFN-α treatment would affect the cell count of the 
cochlear cells. Figure 27 shows an initial increase in the cell count at 6hr in the sham-treated and 
200U/ml-treated groups. However, at the same time point, there was apparent reduction of cell 
count after treatment with 2000U/ml IFN-α, which continued to reach a maximum reduction at 
48hrs. After 12 hrs, the trend in cell count reduction was almost the same for both doses of IFN- 
α.  
Table 25 shows the output for two-way ANOVA which revealed significant differences 
for the effect of both dose and time on the cochlear cell count (P= 0.000 in both cases). However, 
the interaction showed no significant effect (P=0.228), which means that the dose and time affect 
the cochlear cell count independently.  
Post hoc testing (Table26) shows that there was significant differences between sham and 
both 200 and 2000U/ml of IFN- α; however there was no significant difference between 200 & 
2000U/ml (P=0.00, 0.00, and 0.169 respectively). On the other hand, levels of time showed 
significant differences between 6 & 24hrs and 6 & 48hrs only (P=0.019 & 0.002, respectively) 
(Table 27) 
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Figure 27: Cell count change across time points for different doses of IFN- α 
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Table 25: Output of two-way ANOVA for cell count 
Variable           df Mean Square F-value Significance 
Dose 2 2.837E+11 58.301    0.000 
Time 3 9.524E+10 19.570    0.000 
Dose X time 6 7185185185 1.476     0.228 
*: The mean difference is significant at the 0.05 level 
 
 
 
 
 
Table 26: Post hoc analysis for the effect of dose on cell count 
   
Levels of dose Std Error      Significance 
Sham-IFN200* 47441.26264 0.000 
Sham-IFN2000* 47441.26264 0.000 
IFN200-IFN2000 47441.26264 0.169 
*: The mean difference is significant at the 0.05 level 
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Table 27: Post hoc analysis for the effect of time on cell count 
   
Levels of time Std Error Significance 
6-12hrs 71072.03788 0.188 
6-24hrs* 71072.03788 0.019 
6-48hrs* 71072.03788 0.002 
12-24hrs 71072.03788 0.269 
12-48hrs 71072.03788 0.054 
24-48hrs 71072.03788 0.388 
*: The mean difference is significant at the 0.05 level 
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5.0   CHAPTER V: DISCUSSION 
The study was designed to investigate the signaling pathway of IFN-α in the cochlear cell line 
and, in particular, the study was aimed at: first, determining if the cochlea has receptors for IFN-
α that might lead to the expression of IFN genes including IFN-α, IFN-β, and IFN-γ and if IFN-α 
acts directly or indirectly through IFN-β and IFN-γ. Second, the study aimed to detect those 
genes or markers that can be stimulated by the effect of IFN-α and if the cochlear cell count 
would be changed by the effect of IFN-α. In addition, a subsidiary goal was to confirm the 
presence of specific markers for the cochlear cell line.  
As expected, the fold-change calculation reflected more than two-fold increases in the 
expression of most of the hair cell markers which indicates that viable hair cells grew in the cell 
culture used in the current experiment.  
The results of experiment-1, using small doses of IFN-α (20, 40, 80U/ml) showed less 
than two-fold increase in a subset of the IFN-α-induced genes (TNF-α, ICAM, Caspase-3 or 
Bax). This indicates that IFN-α in small doses did not induce expression of some of the IFN-α-
induced genes such as inflammatory genes and apoptotic genes. 
However, the results of experiment-2 using higher doses of IFN-α (200 & 2000 U/ml) 
reflected more than two-fold increases in the inflammatory markers (ICAM1& TNF-α), immune 
response marker (MHC-I) as well as some apoptotic markers (Fas & caspase-3 genes). The 
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results also reflected significant fold-increase of IFN-α1 gene, IFN-β gene with no significant 
increase of type II-IFN (IFN-γ). This might suggest that IFN-α acted directly on the cochlear cell 
line, not through IFN-γ; however its action through IFN-β genes is more likely. These results 
suggest that high doses of IFN-α stimulated the IFN-α receptors either directly or through IFN-β, 
led to induction of inflammatory response, immune response and apoptosis of the cochlear cells, 
reflected in the reduction of the cell number.  
The results also showed significant effects of both the dose and the time of IFN-α 
treatment on the pattern and amount of expression of some of the IFN-α-induced genes. 
The following section will discuss the results of experiment-2 in terms of each research 
question and compare them to the results of experiment-1.   
5.1 Dose the cochlear cells have receptors for IFN-α? 
One subtype of IFN-α was tested to detect the presence of IFN-α receptors in the cochlear cell 
line, i.e., the IFN-α1 gene. The results showed more than two-fold increases in the expression of 
the IFN-α1 gene (Figure 18). This increase was more apparent in the case of the IFN2000 group 
than in the IFN200 group. These findings suggest that the dose of IFN-α affects the level of 
expression IFN-α1 and also indicate that the cochlear cells have receptors for IFN-α.  
However, not only the dose can cause differences in the effects of IFN-α, it can be the 
type of IFN used or the associated disease that induces different biological action. For example, 
Kaygusuz, et al. (2004) found no effect of IFN-α on the hearing threshold of patients with 
chronic active hepatitis B treated with IFN-α2b/day (the cumulative dose was about 720 million 
units over 6 months). On the other hand, Johnson, et al. (2008) reported a case of bilateral SNHL 
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and vestibular dysfunction in a patient receiving the same type of IFN-α with similar cumulative 
dose for the treatment of hepatitis C. This suggests that the associated disease, hepatitis C versus 
hepatitis B, could be the determinant factor in causing hearing impairment, not the dose of the 
IFN-α.  
In the current study, the IFN-α1 gene was the type of IFNs that were expressed, not the 
IFN-α2b, which might have another distinctive pathway. The differential expression of 
individual IFN-α subtypes was due to distinct nucleotide substitutions in the promoter of IFN 
genes  (Au, Yeow, & Pitha, 2001;  Au, Su, Raj, & Pitha, 1993; Civas, Genin, Morin, Lin, & 
Hiscott, 2006; Lopez, Reeves, Island, Bander, Christelt, et al., 1997) as well as the presence of 
negative regulatory sequences located in the upstream (previous location) promoter regions of 
some IFN-α subtypes  (Lopez, Island, Drouin, Bandu, Christeff, et al., 2000) (details about this 
issue are outside of the scope of the current study). However, the possibility that those patients 
with hepatitis C are more vulnerable to develop SNHL by IFN therapy cannot be excluded; 
further investigations are needed to delineate this vulnerability.  
In addition, the results of the current study appear to contradict with the results from 
Akyol, et al. (2001) who failed to find pathological changes in the organs of Corti of albino 
Swiss mice treated by IFN-α. The authors investigated the effect of IFN-α, using audiological 
and histological approaches, but these methods might not be the most accurate approaches to 
precisely rule out the influence of IFN-α on hearing—an effect that can be determined more 
precisely at the molecular level. However, the audiological and the histopathological changes 
observed in their study might be the outcome of the expression of some IFN-stimulated genes 
that led to a shift in the APR threshold after IFN-α treatment. Otoacoustic emissions would be a 
more precise tool to detect early changes if any in the cochlea.  
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In conclusion, the IFN-α1 gene was detected in the cochlear cell line, which suggests that 
the cochlea has receptors for IFN-α. The expression of this gene in the cochlear cell line was 
dose and time dependent which might lead to subsequent expression of other genes with diverse 
reactions at different time points.  
5.2 Did IFN-α act directly on the cochlear cell line? 
Two genes were tested to answer this question, including IFN-β and IFN-γ genes. 
5.2.1. Expression of IFN-β gene 
The results revealed more than two-fold increases in the expression of IFN-β gene (about 5 folds 
by 48 hrs in the case of 200U/ml & 11 folds in the case of 2000U/ml dose)  (Figure 19). It is 
interesting that the pattern of gene expression was not only identical for both doses, but also very 
similar to the pattern of expression in the case of the IFN-α1 gene (Figure 18). This might be due 
to the fact that all type I interferons (IFN-α, IFN-β, and IFN-ω) bind to a common receptor called 
IFNR, which is formed of two subunits (α subunit and β subunit) and elicit a common set of 
signaling events that ultimately regulate the expression of common biological activities (Novick, 
Cohen, & Rubinstein, 1994; Stark, Kerr, Williams, Silverman, & Schreiber, 1998; Uze, Lutfalla, 
& Gresser, 1990). However, this is not always the case; there is accumulating evidence that 
significant differences among the effects of distinct Type I IFNs in vitro and in vivo exist 
(Platanias, 1995). In particular, IFN-β induces a selective association of a tyrosine-
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phosphorylated protein (p100) with the α-subunit of the receptor, which might result in a 
distinctive pathway for IFN-β (Platanias, Uddin, & Colamonici, 1994).  
The expression of IFN-β as a result of IFN-α treatment can be explained in terms of two 
levels: First at the cellular level: IFN-β and IFN-α are secreted from the same type of cells, 
which are the DCs, in particular the plasmacytoid cell subtype of dendritic cells (pDCs). If the 
cochlear cell line has this type of cells; upon stimulation by IFN-α, the DCs will secrete IFN-β. 
The secretion of IFN-β may have a negative feedback on the production of IFN-α1, decreasing 
its level, which might explain the relatively low expression of IFN-α gene in the same time 
window (the fold-increase of IFN-β was more than that of IFN-α1).  However, according to the 
available literature to date, no evidence confirms that DCs are inhabitants of the inner ear. The 
results of the current experiment as it will be mentioned later support the presence of the DC 
cells in the cochlea as reflected by the pronounced expression of the MHC-I gene, which is a 
marker for the immune response. MHC-I are known to be present on the surface of the APCs, 
among which are the DC cells. 
Second at the molecular level: the expression of the IFN-α and IFN-β genes is regulated 
at transcriptional (during copying the mRNA from DNA) and post-transcriptional (after 
formation of mRNA) levels. The family of interferon regulatory factors (IRFs) is the most 
important transcriptional factors that regulate the expression of type-I IFN, in particular, IRF1, 
IRF3, and IRF7. The expression of IFN-α gene is associated with activation of IRF3, which in 
turn will homo-or heterodimerize with IRF-7 and translocate to the nucleus, where they stimulate 
transcription of IFN-β (Grandvaux, Servant, tenOever, Sen, & Balachandran, 2002; Lin, 
Heylbroeck, Pitha, & Hiscott, 1998; Lin, Mamane, & Hiscott, 1999; Peters, Smith, Stark, & Sen, 
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2002; Weaver, Kumar, & Reich, 1998; Yoneyama, Suhara, Fukuhara, Fukuda, Nishida, & Fujita, 
1998).  
The expression of IFN-β in larger amounts than IFN-α1 might be in agreement with what 
has been reported by Kanda et al. (1994) who found that the incidence of hearing impairment 
was more associated with IFN-β than with IFN-α. However, in another study, Kanda et al. (1995) 
found no difference in the incidence of hearing loss between patients treated with IFN- α and 
those who were treated with IFN-β. This similarity might be consistent with the similar pattern 
of expression between IFN-α and IFN- β in the current study. 
In conclusion, IFN-β gene expression in the cochlear cell line can be induced by IFN-α 
treatment either by stimulation of DC cells or through IRF3 signaling pathway. The apparent low 
expression level of IFN-α in comparison to that of IFN- β might suggest that the IFN-β took over 
the action of IFN-α1, i.e., the action of IFN-α on the cochlear hair cell line can be mediated by 
IFN-β. This means that IFN-α can act directly on its receptors or by enhancing the secretion of 
IFN-β. Gene-gene interaction study might be helpful in delineating this relation between both 
genes. The effects of dose and time were significant on the IFN-β gene expression, which means 
that the IFN-β gene expression was dose and time dependent.  
5.2.2. Expression of IFN-γ 
Although it is well known that type I-IFN enhances the secretion of IFN-γ by mediating the 
activation of NK and T cell responses (Biron, Nguyen, Pien, Cousens, & Salazar-Mather, 1999; 
Orange & Biron, 1996), the results of the current study revealed less than two-fold increases in 
the IFN-γ gene expression (Figure 20). This means that the growing cells from the cochlear cell 
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line used in the current experiment did not produce IFN-γ.  IFN-γ can be produced in the inner 
ear by induction of labyrinthitis in experimental animals (e.g., Gloddek et al., 2002; Pawankar, et 
al., 2004) and human subjects (Lorenz, et al., 2002; Solares & Tuohy, 2005) as a result of 
antigen challenge in the inner ear or associated with autoimmune SNH, respectively. Moreover, 
the upregulation of IFN-γ in the inner ear in these studies was associated with upregulation of 
ICAM1 (Pawankar, et al., 2004) and MHC-I (Gloddek et al., 2002), which means that IFN-γ was 
associated with induction of inflammatory and immune responses in the inner ear. These findings 
provide evidence for the production of IFN-γ in the inner ear in association with inner ear injury 
or pathology, which is not the case in the current study. The events in the current study were not 
based on ongoing antigen challenges or stimulation of the immune system cells (the cochlear cell 
line used in the current study was not exposed to any kind of antigen or cell injury), rather they 
reflected molecular or genetic signaling events and this may explain the difference in findings. 
At the molecular level, the results of the current study might be in agreement with the 
study of Nguyen, Cousens, Doughty, Pien, Durbin & Biron (2000) who found that IFN-α and 
IFN-β did not enhance the expression of IFN-γ. They attributed this negative regulation between 
type I-IFN (IFN-α & IFN-β) and type II-IFN to STAT1, which is involved in the signaling 
pathway of type I-IFN because when these two cytokines had an alternative signaling pathway 
that did not involve STAT1, they promoted the expression of IFN-γ. Therefore, it can be argued 
that IFN-α and IFN-β used the Jak-STAT signaling pathway with activation of STAT1 in the 
cochlear cell culture, and hence, they were not able to promote the expression of IFN-γ. This 
pathway needs to be tested in order to elucidate this issue. 
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Treatment of the cochlear cell line with IFN-α did not induce expression of the IFN-γ 
gene, which suggests that IFN-γ did not mediate the action of IFN-α. Instead, IFN-α might have 
acted directly or through IFN-β as was mentioned in the previous section.  
5.3 Did IFN-α induce expression of inflammatory markers? 
To answer this question, the expression of two inflammatory genes was examined, including the 
ICAM1 gene and the TNF-α gene. 
5.1.1 Expression of ICAM1 gene  
The results of experiment-2 revealed more than two-fold increases in the expression of the 
ICAM1 gene as a result of IFN-α treatment of 2000U/ml; whereas, a dose of 200U/ml showed 
less than two fold-change (Figure 21).  In both cases, the maximum fold-increase was at12hrs, a 
point at which both IFN-α and IFN-β showed maximum decline in their levels (Figures 18 & 19). 
The level of ICAM1 expression started to increase at the beginning (for instance 6hrs) then 
reached maximum at 12hrs and declined to its minimum level at 48hrs, a pattern that is similar to 
the pattern of changes in the ICAM1 concentration in other studies. For example, Suzuki and 
Harris (1995) found that the concentration of ICAM1 in the inner ear following antigen 
challenge was weak at 6hrs and reached its maximum on the second day, and then it faded away. 
Also, Pawankar et al. (1998 & 2004) observed the same pattern of expression of ICAM-1 
molecules in different parts of the inner ear following an antigen challenge and IFN-γ treatment.  
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These previous studies found that the expression of ICAM1 was concomitant with the 
expression of IFN-γ. The authors suggested that IFN-γ plays an important role in the expression 
of the ICAM1 gene. The IFN-γ gene was not detected in the current experiment; however the 
observation that ICAM1 reached its maximum level at 12hrs, where both IFN-α and IFN-β 
expression reached their minimum levels suggests the possibility of a relationship between 
ICAM1 and both IFNs. Notably, the levels of ICAM1 maximally declined at 24 & 48hrs, 
whereas both IFNs reached their highest levels. It seems that once the level of both IFNs 
declined, ICAM1 molecules increased and the reverse is correct. This might be explained by the 
presence of a negative feedback between the expression ICAM1 and the expression of both 
IFNs. It is known that the production of cytokines is usually transient, and never can be sustained 
to initiate a certain action or to stimulate another cells to induce different cytokines (Guttermann, 
1995), which might be the case with ICAM1 and both IFNs in the current study. The scenario of 
the events could be as follow: the expression of both IFNs enhanced the expression of ICAM1, 
the expression of which might have led to a transient decline in the IFNs’ levels (for example at 
12hrs). The function of ICAM1, as inflammatory molecules, is mainly the recruitment of 
inflammatory cells and inflammatory mediators to the scene of inflammation; once these 
mediators are formed, ICAM1 molecules have no further role. This might explain the transient 
increase in their levels in the current experiment and other studies.  
In addition, the association between ICAM1 and IFNs was not limited to that between 
IFN-γ and inner ear pathology, but there is also an association between them in retinal pathology. 
For instance, Lee, Hooper, Kump, Hayashi, Nussenblatt et al. (2006) found that there was a 
concomitant expression of both IFN-β and ICAM1 in the sera of patients with retinal vasculitis. 
There was also an association between IFN-α and ICAM1 in the islet endothelial cells of the 
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pancreas in type I diabetes mellitus (Chakrabarti, Huang, Beck, Henrich, McFarland, et al., 1996; 
Foulis, Farquharson, & Meager, 1987; Somoza, Vargas, Roura-Mir, Vives-Pi, Fernandez-
Figueras, et al., 1994). Therefore, IFN-α and IFN-β might have enhanced the expression of the 
ICAM1 molecules, which in turn led to the reduction of these two cytokine levels by a negative 
feedback mechanism.  
5.3.2.   Expression of TNF-α gene  
The pattern of expression of the TNF-α gene was very similar to the ICAM1 gene expression 
(Figure 22). Therefore, it can be argued that both TNF-α and ICAM1 as inflammatory genes 
were expressed in the same time and they had a similar relationship (negative feedback) with 
IFN-α and IFN-β. Also, TNF-α expression was time-dependent and dose-independent. IFN-α has 
an inhibitory effect on the TNF-α gene expression in vivo and in vitro, producing an anti-
inflammatory effect (Abu-Khabar, Armstrong, & Ho, 1992; Larrea, Garcia, Qjan, Civiera, & 
Prieto, 1996). The findings of these authors’ studies appear to contradict the conclusion that was 
drawn from the current study about the presence of a feedback between TNF-α and IFN-α & 
IFN-β as in case of ICAM1. However, the pattern of changes observed in the expression of all 
four genes is more consistent with a feedback mechanism than with an inhibitory mechanism. If 
the case was an inhibitory mechanism, the level of IFN-α and IFN-β would not decline when the 
levels of ICAM1 & TNF-α were high (as was observed at 12hrs); instead, the levels of both IFNs 
should remain high all the time, as long as the levels of both ICAM1 & TNF-α are low (in the 
case of an inhibitory effect).  
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In agreement with the results of experiment-2 is the study of Ren, Jin, Piao, and Piao 
(2007) who found that IFN-α therapy significantly increased the level of TNF-α and IFN-γ in 
patients with hepatitis B. This means that IFN-α promotes the production of TNF-α to 
accomplish its antiviral effect on the hepatitis B virus, which might support the feedback 
relationship between TNF-α and both IFNs. 
Also, other studies showed that both IFN-α and TNF-α share some activities. For 
instance, a series of studies reported that combined treatment with IFN-α and TNF-α exhibited 
much stronger antitumor effects (Fiers,1991; Muro, Naomoto, & Orita, 1991; Naomoto, Tanaka, 
Fuchimoto, & Orita,1987; Orita, Ando, & Kurimoto, 1987; Yasuoka, Naomoto, Yamatsuji, 
Takaoka, Kimura, et al., 2001). The authors of these studies found that the two cytokines had the 
same signaling pathway to induce their apoptotic or antitumor effect. This reflects that both of 
these cytokines have synergetic or additive effect and not inhibitory effects as it was reported by 
Abu-Khabar, et al. (1992) and Larrea, et al. (1996). 
Therefore, it can be concluded that IFN-α have induced the expression of the TNF-α gene 
in cultured cochlear cells. It appeared that a negative feedback relationship exists between them. 
However the nature of their action together, either inflammatory, anti-inflammatory or apoptotic 
cannot be determined within the scope of the current study. Further signaling pathways need to 
be tested to resolve this issue. Conclusively, the results and the supportive evidence from 
previous studies suggest that IFN-α treatment resulted in expression of both ICAM1 & TNF-α 
genes (inflammatory markers) in the cultured cochlear cells of this experiment and these genes 
had a negative feedback on IFN-α1 and IFN-β expression.   
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5.4. Did IFN-α induce expression of immune response markers? 
To address this question, the expression of MHC-I gene was tested. There was much more than 
two-fold increases in the expression of the MHC-1 encoded by H2K1 gene in the cochlear cells 
treated by IFN-α. The expression was relatively high in both doses of IFN-α and over all time 
points, which might suggest that MHC-I was expressed constantly in the treated cochlear cell 
culture (Figure 23). The function of the MHC-I molecules is to present processed antigen to 
cytotoxic T cells and bind to CD8 on the surface of T-cells. IFN-α induces activation of CD8+ T-
cells and thus promotes their cytotoxicity, with subsequent expression of the MHC-I molecules 
(York, Odom, Murphy, Ives, and Wente, 1999). In addition, IFN-α stimulates the DCs, which are 
considered professional APCs (Cella, Facchetti, Lanzavecchia, & Colonna, 2000). Therefore, 
IFN-α can enhance antigen presentation to T-cells with a subsequent expression of MHC-I and 
phagocytosis of a foreign antigen (Biron, 1998).  
At the molecular level, the promoter (i.e., a part of the gene with which a stimulating 
molecule will attach to induce expression of that gene) of the MHC-I genes contains an 
interferon response sequence (IRS), which leads to expression of MHC-I once IFN-α is 
introduced (Ten, Blank, Le, Kourilsky, & Israël, 1993). Therefore, treatment of the cochlear cell 
culture with IFN-α most probably led to expression of MHC-I gene. 
The results of the current study may be in agreement with what has been documented by 
many studies that MHC-I is a “hallmark” of type I-IFN, including IFN-α (Brucet, Marqués, 
Sebastián, Lloberas, & Celada, 2004). In addition, IFN-α treatment has been found to be 
important for clonal expansion and survival of the CD8+ T-cell population (MHC-I binds to the 
surface of these cells) in an antigen-independent manner, a mechanism called “bystander effect” 
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(Parronchi, Mohapatra, Sampognaro, Giannarini, Wahn, et al.,1996; Tough, Borrow, Sprent, 
1996). Although this bystander effect is not as powerful as a response during viral infection, it 
still represents a unique mechanism of controlling an adaptive immune response (Tough et al., 
1996). Moreover, IFN-α has been found to cause alteration of the MHC with increased 
expression of class I molecules on the tumor cells (Oberg, 1992). All these findings support the 
notion that IFN-α is a major enhancer of T-cell activation and hence, it is a potent inducer of 
MHC. Furthermore, in agreement with the current study, other studies on both animal and human 
have indicated that IFN-γ and IFN-α may upregulate MHC-I molecules on various types of 
normal cells (Jarosinski and Massa, 2002; Keir et al, 2002; Ljunggren and Anderson, 1998) and 
tumor cells (Abril., Mendez, Garcia, et al., 1996; Anderson, Elder, Brown et al., 2002; Atta, 
Irving,Powell, et al., 1995). 
Notably, lymphocytes (which are the cells of the adaptive immune response) are not 
normally present in the cochlea; however, the cochlea’s innate immunity may be responsible for 
initiating the adaptive immune response with subsequent recruitment of lymphocytes. Therefore 
treatment with IFN-α, which is well known by its priming action (initiates the innate immune 
response) and its bystander effect (needs no antigen) will promote the development of adaptive 
immune response with subsequent lymphocytic activation, leading to MHC-I production in the 
cochlear cell culture regardless of the absence of antigen exposure. This conclusion might 
explain the constant expression of MHC-I over all the time points and in both doses (200 & 
2000U/ml).  
Many studies have shown the involvement of lymphocytes, including CD+4 & CD+8 T-
cells with the production of IFN-γ and ICAM1 in the pathogenesis of immune-mediated inner ear 
disorders in human subjects as well as in experimental animals (Arnold, Pfaltz, & Altermatt, 
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1987; Gloddek et al., 1999; Lorenz et al., 2002; McCabe & McCormic, 1984; Yamanobe & 
Harris, 1992). This association between hearing loss and the immune response suggests that IFN-
α can cause hearing impairment by promoting the innate as well as the adaptive immune 
responses in the cochlea. Therefore, IFN-α can induce an immune response in the cochlea. 
5.5 Did IFN-α induce expression of apoptotic markers? 
Three markers were examined to address this question, including Fas, caspase-3 and Bax genes. 
5.5.1     Expression of Fas gene 
The results of the current study showed more than two-fold increase in the expression of Fas 
gene only at the 12hrs time point in the case of IFN2000, and less than two-fold increase with 
IFN200 or other time points in either case (Figure 24). This transient pattern of expression is 
more or less similar to the pattern of expression of both ICAM1 & TNF-α. Notably, there were 
many events occurring at the 12hrs time point: IFN-α1 and IFN-β reached their minimal level of 
expression, ICAM1, TNF-α and Fas genes reached their maximum levels of expression. 
Therefore, it can be argued that Fas gene expression has the same negative feedback relationship 
with both IFN-α1 and IFN-β. The scenario of these events can be as follows: treatment of the 
cochlear cell culture with IFN-α led to the expression of IFN-α1 and IFN-β, which stimulated the 
expression of inflammatory genes (ICAM1 & TNF-α). By their roles as inflammatory genes, an 
inflammatory reaction started that drove the cells into apoptosis by concomitant expression of 
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the Fas gene. It is well-known that Fas-FasL system is a common extrinsic pathway of cell death, 
by which IFN-α induces apoptosis (Fulda & Debatin, 2002; Inaba, et al, 2004). Also, the Fas-
FasL system occurs in the cochlea due to aminoglycoside and cisplatin ototoxicity (Van de 
Water, Nguyen, Shoemaker, Schipor, et al., 2001). 
Moreover, there is evidence about the presence of Fas in the inner ear following repeated 
doses of IFN-γ to inner ear cell culture in vitro and the induction of immune-mediated 
labyrinthitis in vivo (Bodmer, et al., 2002; Bodmer, et al., 2003). The authors of these studies 
noticed dramatic changes in the distribution of Fas in the cellular components of the organ of 
Corti but no changes in the transcription of the gene encoding Fas (by using PCR). The 
distribution of Fas following IFN-γ-stimulation was consistent with the recruitment of preformed 
Fas from intracellular compartments, e.g., endoplasmic reticulum into the cytoplasm and the 
plasma membrane rather than its biosynthesis as a consequence of genetic expression. Bodmer et 
al. (2003) concluded that expression of Fas on the plasma membrane might indicate the 
involvement of Fas in the protection of the inner ear from stress by autoimmune or inflammatory 
responses. This protective role of Fas also was suggested to be exerted in the anterior chamber of 
the eye (Griffith, Yu, Herndon, Green, & Ferguson, 1996). A supporting finding for these 
suggestions is that mice with deficient Fas-FasL system show immune reactions with progressive 
hearing loss (Trune, Craven, Morton & Mitchell, 1989; Ruckenstein, Keithley, Bennett, Powell, 
Baird & Harris, 1999). This means that the absence of Fas makes the inner ear more vulnerable 
to immune reactions.  
This protective role of Fas looks to be unlikely in light of the current results as the 
expression of Fas occurred simultaneously with the expression of the inflammatory genes, which 
are indicators of an inflammatory response, the end result of which is usually cell death. Also, 
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the reduced cell viability reflected by reduced cell count (discussed in a later section) should 
have resulted from cell death that most likely was initiated by Fas as a cell death orchestrator, not 
as a protective agent. The expression of the Fas gene was time-dependent but not dose-
dependent. 
5.5.2. Expression of caspase-3 gene  
Caspase-3 is an executioner caspase that cleaves cellular substrates following either the extrinsic 
or the intrinsic pathway (Budihardjo, Oliver, & Lutter, 1999; Vaux & Strasser, 1996); therefore 
its expression does not specify which pathway of cell death has taken place. The results of 
experiment-2 revealed more than two-fold increase in the gene expression of caspase-3 that 
started at 6hrs, reaching its maximum at 12-24hrs and declined to reach its minimal level at 
48hrs (Figure 25). This pattern of expression of caspase-3 gene suggests a sequence of events 
that started earlier with the increased expression of IFN-α1 and IFN-β genes, followed by an 
increase of inflammatory markers and the expression of death molecules (Fas) that orchestrated 
the extrinsic pathway of apoptosis. This extrinsic pathway stimulated a series of downstream 
(later in the sequence) caspases, among which was the executioner caspase-3. The caspase-3 
gene causes cleavage of proteins necessary for cell survival, resulting in cell death.   
The results of this experiment are in agreement with most of the studies that investigated 
the extrinsic pathway of apoptosis (Budihardjo, Oliver, Lutter et al., 1999; Cao, Luo, Nagayama, 
et al., 2002; Lesuisse & Martin, 2002). Caspase-3 activation has been detected also in hair cells 
damaged by aminoglycosides (Cunningham, Cheng, & Rubel, 2002; Lee, Nakagawa, Kim, et al., 
2004; Mangiardi, McLaughlin-Williamson, May, et al., 2004), cisplatin (Zhang, Liu, Ding, & 
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Salvi, 2003), and acoustic trauma (Hu, Henderson, & Nicotera, 2002; Nicotera, Hu, & 
Henderson, 2003).  
In conclusion, the results suggest that IFN-α induced expression of caspase-3 gene, which 
might be through a sequence of events that started by the induction of inflammatory markers and 
engagement of the Fas gene, which orchestrated an extrinsic pathway of cell death that involved 
caspase-3 as an executioner caspase. 
5.5.3.   Expression of Bax gene 
The results showed less than two-fold increase in the expression of Bax gene (Figure 26). Bax is 
a pro-apoptotic Bcl-2 family member that can trigger the intrinsic pathway of apoptosis. Because 
Bax is activated only during the intrinsic pathway, it can be assumed that the cells of the cochlear 
cell line in the current experiment did not undergo apoptosis through the intrinsic pathway. 
However, this cannot be totally ruled out for two reasons. First, there was an apparent peak in the 
expression of Bax gene at 24hrs, which might indicate an initiation of the intrinsic pathway of 
cell death, especially because this peak was timed with the expression of caspase-3 gene that is 
involved in both pathways of cell death. Second, the expression of other caspases, such as 
caspase-9 or other proapoptotic genes of Bcl2 family such as Bak or cytochrome-c, needs to be 
examined to confirm or to rule out the occurrence of the intrinsic pathway of cell death. 
           Therefore, the results of experiment-2 suggest that treatment of the cochlear cell culture 
with IFN-α led to expression of the Fas gene, which orchestrated an extrinsic pathway of 
apoptosis. Fas in turn, activated downstream caspases included caspase-3, which is an 
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executioner caspase that cleaved cellular structures leading to cell death. This suggests that IFN-
α was able to induce apoptotic markers in the cochlear cell culture.   
5.6. Did IFN-α reduce the cell count of the cochlear cells? 
The results of experiment-2 also reflected a significant reduction of the cell count as a result of 
IFN-α treatment; however the difference in the cell count between 200 & 2000U/ml was not 
significant. The results also showed evidence for the occurrence of cell death, which was most 
likely initiated by Fas-induced apoptosis, an extrinsic pathway of cell death. On the other hand, 
the Bax gene, which is a marker for the intrinsic pathway of apoptosis, was not expressed in this 
experiment. However, the reduced cell count extended over all time points, especially in the case 
of IFN2000, which might indicate the presence of an alternative pathway of cell death that 
continued over all time points. The persistence of caspace-3 (which is a common caspase in both 
pathways of cell death) over longer time points support the occurrence of apoptosis over an 
extended time period. Notably, the expression of both Fas and caspase genes were not dose 
dependent, which might explain why the reduced cell count did not show significant difference 
between the two doses IFN-α.  
In addition, it is possible that cell death resulted from the immune response mediated by 
IFN-α. The expression of MHC-I occurred across all time points, which indicates that an 
immune reaction was going on along with the reduced cell count. Moreover, the inflammatory 
response might be another cause behind the reduction in the cell viability. In either case (immune 
response or inflammatory response), cell death might have occurred due either to apoptosis or 
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necrosis. Other inflammatory markers as well as markers for necrosis need to be examined to 
confirm this possibility. Likewise, other genes of the intrinsic pathway, such as Bak and caspase-
9, need to be examined to confirm this pathway.  
The reduced cell count noticed over time in case of the control (sham) was most probably 
due to exhaustion of the nutrients in the media; yet there were still significant differences 
between the cell count in case of the sham and either doses of IFN-α.  
5.7. Were the effects of IFN-α dose and/or time dependent? 
Overall, the effects of IFN-α on the expression of IFN-α-induced genes were dose and time 
dependent in most cases. Also, the pattern of changes in the gene expression across hours look to 
be identical for both doses (200 & 2000U/ml). Notably, both doses induced upregulation of most 
of the IFN-α-induced genes even if the fold increase did not reach the cut off (2 folds). These 
results, when viewed together with the results of experiment-1 show similar, yet opposite effects. 
That is, in experiment 2, using higher does, there was an increase in the fold (i.e., increase 
expression or upregulation of the genes); yet with experiment-1, with very low doses, a decrease 
or downregulation of these genes were noticed.   
These findings may be consistent with the dose-dependent response typically seen with 
cytokines treatment. For instance, low-dose treatment has a stimulating effect, whereas, high-
dose produces tolerating or suppressant energies (Biron, 2001; Havell & Spitalny, 1983a; 1983b; 
Taylor, & Grossberg, 1998). This observation did not point to an absolute stimulation or an 
absolute depression; rather it meant that low and high doses have distinctive outcomes. For 
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example, Yoshino (1996) found that a low dose of IFN-α caused downregulation of delayed 
hypersensitivity and cellular infiltration in lymph nodes. On the other hand, high doses were 
found to be clinically effective against neoplasm and against viral infection, but they are poorly 
tolerated by the patients (Tovey, Meritet, Guymarho, & Maury, 1999). Also, it has been 
documented by some studies that systemic administration of low doses of IFN-α during anti-
neolplastic or antiviral therapy will act as a priming cytokines for the host immune system, 
resulting in protection from viral challenge and increase of the tolerance of the patient to the 
effect of IFN-α (Beilharz, McDonald, Waston, Heng, McCeachie, & Lawson, 1997; Ferbas, 
Toso, Logar, Navratil, & Rinaldo, 1994).  
            Theoretically, low-doses of IFN-α mimic the early endogenous priming effect by innate 
immunity versus high-dose treatment that resembles the systemic adaptive immune response, 
which is usually vigorous and more generalized (Tompkins, 1999). The innate and the adaptive 
immunity have distinctive cytokines production and distinctive cellular activation, which might 
make the outcome of low-dose treatment distinctive from the high-dose treatment.  
 This assumption might provide an explanation for some clinical findings associated with 
IFN-α treatment. For example, Kanemaru et al. (1997) used IFN-α to treat patients with severe 
idiopathic SNHL due to viral infection. A significant number of those patients showed complete 
recovery after IFN-α therapy of a total cumulative dose of 30 million units. The recovery of the 
hearing loss in their study was most probably due, first, to enhancement of the antiviral effect 
that in turn overcame the viral assault in the inner ear. This antiviral effect was indicated by the 
concomitant increase in 2,5 oligoadenylate  synthetase (2,5 A-S) activity. Second, the recovery 
of the hearing loss might be attributed to a different pathway of IFN-α in the inner ear when it is 
used in low doses. This different pathway might have led to induction of other genes such as 
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anti-inflammatory or anti-apoptotic genes with subsequent recovery of the hearing loss. There is 
evidence from other studies that IFN-α has an antiapoptotic effect by enhancing the expression 
of some anti-apoptotic genes of the Bcl-2 family (Imam, Gobl, Eriksson, & Oberg,, 1997).  
Furthermore, the results of experiment-2, in particular the expression of the inflammatory 
genes, the immune-response genes as well as the apoptotic genes by high doses,  may be 
consistent with a considerable number of studies that found an association between SNHL and 
IFN-α therapy, especially in patients with hepatitis C viral infection (Elloumi, et al., 2007; 
Piekarska, et al., 2007; Wong, et al., 2005; Formann, et al., 2004; Okanoue, et al., 1996; Cadoni, 
et al., 1998; Kanda, et al.,1994). The authors of these studies attributed this hearing loss to the 
inflammatory response, the immune response or the direct toxic effect of IFN-α on the hair cells 
that might have led to apoptosis. The reported cumulative dose that was found to be associated 
with the occurrence of SNHL was more than 100 million units (i.e. about three times the 
cumulative dose used in the treatment of SNHL in the study of Kanemaru et al. (1997).  
Therefore, it can be concluded that IFN-α, when used in small doses, can produce different 
effects on the cochlear cells from when it was used in large doses. This suggests that IFN-α has 
dual actions; protective in small doses and harmful in large doses.  
The dose and the administration schedule of IFN-α treatment may play an important role 
on its biological and therapeutic effects by shaping the innate and the adaptive immune 
responses. In particular, low-dose of IFN-α can be used to protect against viral infection or 
immune-mediated disorders. On the other hand careful observation and follow ups might be 
necessary in case of long-term, high-dose therapy of IFN-α; two measures that can be applied to 
protect against hearing impairment.  
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6.0 CHAPTER VI: SUMMARY AND CONCLUSIONS 
6.1 SUMMARY AND IMPACT OF THE CURRENT STUDY 
In summary, previous studies have demonstrated that IFN-α can cause hearing impairment in 
patients receiving IFN-α therapy. The association between IFN-α therapy and hearing 
impairment was mainly in patients with hepatitis C. The results of the previous studies were 
diverse and inconsistent, while some demonstrated that IFN-α caused hearing impairment, others 
showed its therapeutic usefulness in the treatment of idiopathic SNHL. Different mechanisms 
have been suggested to explain the association between IFN-α and hearing impairment. These 
mechanisms included direct toxic effect of IFN-α on the cochlear structures that led to apoptosis 
of the cochlear cells, inflammatory reaction and/or immune response. 
           The current study investigated the signaling pathway of IFN-α in the cochlear cell line to 
shed light on these various mechanisms. The cell culture derived from the HEI-OC1 cochlear 
cell line was treated by different doses of IFN-α and at different time points. Using relatively 
small doses (20, 40, & 80U/ml) at five time points (3, 6, 12, 24, & 48hrs) in experiment-1 
showed less than two-fold increase of the tested genes (IFN-γ, ICAM, TNF-α, caspase-3 or Bax). 
This can be explained by the inability of small doses of IFN-α to cause enough stimulation of 
IFN-α receptors to induce subsequent expression of other IFN-α-induced genes.  
 135 
 
           However, the results of experiment-2, using large doses resulted in more than  two-fold 
increase in other types of IFN genes as well as IFN-α-stimulated genes, including the 
inflammatory genes (ICAM & TNF-α), immune response gene (MHC-I), and apoptotic genes 
(Fas & caspase-3). These outcomes suggest that the cochlear cells have receptors to IFN-α, 
which were stimulated by relatively higher doses of IFN-α. Stimulation of these receptors led to 
the expression of IFN-α1 and IFN-β genes. These genes led to initiation of an inflammatory 
response as well as an immune response that might have led to cell death of the cochlear cells as 
revealed by the reduced cell count. 
The inflammatory response, the immune response and apoptosis are the underlying 
mechanisms involved in the hearing impairment noticed in patients under IFN-α therapy. The 
immune response was the most pronounced response as it has been reflected by the expression of 
the MHC-I gene which showed the highest expression level among the other genes. The 
inflammatory and the apoptotic responses looked to be transient as it has been revealed by the 
expression of ICAM-1, TNF-α, Fas and caspase-3, which showed peak expression at the same 
time point (12hrs). Particularly at this time point, both IFN-α1 and IFN-β genes showed 
maximum decline in their expression level, which might indicate the presence of a negative 
feedback between the occurrence of the inflammatory and the immune responses and the level of 
both IFNs. It can be suggested that this feedback relationship functions to limit both responses 
and protect against further insult. This conclusion is supported by the notion that the production 
of cytokines is usually transient, and never can be sustained, to initiate a certain action or to 
stimulate other cells to produce different cytokines (Guttermann, 1995).  Also, this pattern of 
responses that occurred in the same time might reflect that of IFN-α induced inflammatory, 
immune as well as apoptotic responses simultaneously not as a sequence of events.  
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All these responses might have led to cell death that was reflected in the reduction of cell 
count noticed in all time points and occurred with both doses of IFN-α. Although there was 
significant increase in the markers of the extrinsic pathway of apoptosis, the occurrence of the 
intrinsic pathway cannot be ruled out because the reduction of cell count was continuous over all 
time points (i.e., beyond the time points at which extrinsic pathway markers were expressed), 
especially with high dose. Likewise, the inflammatory response, as well as the immune response, 
can drive the cells to cell death, which most likely was through necrosis. Further markers for the 
intrinsic pathway of cell death as well as markers for necrosis need to be examined to rule out or 
to prove the occurrence of either intrinsic pathway and/or necrosis.  
The effect of IFN-α treatment on the expression of most of the genes included in the 
current study seemed to be dose and time dependent; the dose of IFN-α has been found to 
determine the nature of its effect.  
Therefore, the current study implies that IFN-α can affect hearing by different 
mechanisms including inflammatory reaction, immune response, and apoptosis. These 
mechanisms might occur as a sequence of events or occur simultaneously. The dose and the time 
of IFN-α treatment influence the outcome of its effect, which implies that IFN-α in small doses 
can be used in the treatment of some immune-mediated disorders as well as viral infection of the 
inner ear. It also implies that pre-treatment hearing evaluation as well as close monitoring of 
hearing function in patients undergoing long-term, high-dose IFN-α therapy might be necessary 
to avoid or to minimize its harmful effect on hearing. The decision whether to continue or to stop 
IFN therapy needs to be made carefully by the physician according to the patient medical 
condition. If the treatment needs to continue, physicians should be aware of the possible ototoxic 
effects of IFN-α requiring appropriate surveillance. 
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6.2 DIRECTIONS FOR FUTURE RESEARCH 
- Better design can be used to investigate the signaling pathway of IFN-α in the cochlear 
cell line, including more time points, multiple dose regimens that include a wide range of 
doses; most of the IFN-α studies included a wide range of doses that extended from one 
to 100,000U/ml. This will help in determining different biological characteristics of IFN-
α that are largely dependent on its dose. Also, repeated doses might be helpful to mimic 
the actual therapeutic course of IFN-α and to help in magnifying an immune response, if 
any. 
- Different methods of cell count can be used such as flow cytometry.  
- To investigate if the inflammatory/y response, immune response, and the apoptosis occur 
in sequence or simultaneously, specific antibodies can be used to suppress one or both of 
the two first responses (inflammatory or immune or both)  and determine if evidence of 
apoptosis is still there. This can help in inventing new therapeutic agents that might cut 
off this sequence of events. Also it will help in better understanding the underlying 
mechanisms involved in IFN-α therapy. 
- Likewise, markers for other apoptotic pathways such as the intrinsic pathway, as well as 
markers for necrosis need to be examined. 
- Immunohistochemical studies might be helpful in determining the functional effect of 
these genes that affected by IFN-α treatment by detecting their corresponding proteins. 
- Animal models can be used to mimic the biological events that can occur in vivo as a 
result of IFN-α treatment. In addition, animal model for hepatitis C would be the ideal 
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model to simulate the real scenario occurring in patients with hepatitis C undergoing 
IFN-α therapy. 
- Prospective studies that include subjects receiving IFN-α therapy for different diseases 
(such as hepatitis C, hepatitis B, malignancies.etc) need to be run. These patients should 
have their hearing tested before starting the therapy and every three or six months during 
the therapy. The hearing evaluation should include basic audiological testing as well as 
otoacoustic emissions to detect early changes that might occur in the cochlea.  
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APPENDEX A 
LIST OF ABBREVIATIONS 
Abbreviation Meaning 
IFN Interferon 
IFN-α Interferon-alpha 
IFN-β Interferon-beta 
U Unit 
IU  International unit 
B-lymphocytes Bone-marrow lymphocytes 
T-lymphocytes Thymus lymphocytes 
Th- cells Thymus helper cells 
DCc Dendritic cells 
NK Natural killer cells 
CD Clusters of differentiation 
HPSC Hematopoietic stem cells 
BM Bone marrow 
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Ig Immunoglobulins 
RBCs Red blood cells 
Fas folic acid synthesis 
DR Death receptors 
Caspases cysteine-aspartic acid proteases 
FasL Fas-ligand 
Bcl B-cell leukemia 
JAK Janus kinases 
STAT Signal transduction and activators of transcription 
Tyk Tyrosine kinases 
ISGF-3 Interferon stimulated gene factor-3 
P-48 Protein-48 
GAS Gamma activating sequence 
IL Interleukin 
ICAM Intercellular adhesion molecules 
APCs Antigen presenting cells 
MHC-I Major histocompatibility class I 
MHC-II Major histocompatibility class II 
ABR Auditory brainstem response 
ASNHL Autoimmune SNHL 
KLH Keyhole limpet hemocyanin 
ELISPOT Enzyme-linked immunospot 
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FACS fluoresce-activated cell sorter 
PCR Polymerase chain reaction  
DNA Deoxy- ribonucleic acid 
cDNA Cloned/complementary DNA 
RNA Ribonucleic acid 
IFR-3 Interferon regulatory factor-3 
ROS Reactive oxygen species 
NO Nitric oxide 
TNF-α Tumor necrosis factor-α 
HEI-OC House Ear Institute- Organ of Corti 
Hrs Hours 
ml milliliters 
µL micro litter 
BSA Bovine serum albumin 
PBS Phosphate buffered saline 
rt-PCR Real time PCR 
RT Reverse transcription 
ds DNA Double strand DNA 
mRNA Messenger RNA 
CO2 Carbon dioxide 
BSA Bovine serum albumin 
Ct Cycle threshold 
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ANOVA Analysis of variance 
ANCOVA Analysis of the covariance 
DMEM Dulbecco’s modified Eagle medium 
rRNA Ribosomal RNA 
dGTP Deoxy-guanine triphosphate 
dNTPs Deoxy- nucleotide triphosphates  
dUTP Deoxy- undine triphosphate  
MgCl Magnesium chloride 
dATP Deoxy-adenosine triphosphate 
dCTP Deoxy-cytosine triphosphate 
IRS Interferon response sequence 
SDS Signal detection system 
LSD Least significant difference 
STDV Standard deviation 
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APENDEX B 
LIST OF PRIMERS 
Primers are used as complementary sequences to the target sequences in the PCR reaction. 
Therefore, each primer has a complementary sequence to each gene in question. 
A.1 PRIMERS FOR HIAR CELL MARKERS 
These include the followings: 
1. Primer for Myosin-VIIa gene 
- Forward: 5’- CATCCGCAACGACAACTCT -3’  
- Reverse: 5’- TCGATGGCACCACGCTTGTTA -3’. 
2. Primer for Nestin gene: 
- Forward: 5’- TCAGCTGAGCCTATAGTTCAA -3’  
- Reverse: 5’- GCCAGAGCAGTCTCGT -3’. 
3. Primer for connexin26 gene Forward r: 
- Forward: 5’-CTGATGGTCCTGGCGGTGCT-3’  
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- Reverse: 5’-CCTTCTCCTGCGGGAATCCAA-3’. 
4. Primer for Calbindin2 gener: 
- Forward: 5’- TGTGCCTGCGTTGGGTCA -3’  
- Reverse: 5’- CCTAAATCATACAGCGAAGGA -3’. 
A.2 PRIMERS FOR IFN-INDUCED GENES 
These primers include the followings: 
A.2.1 Primers for other types of IFNs 
1. Primer for IFN-α1 gene 
- Forward r: 5’-CTGATGGTCCTGGCGGTGCT-3’  
- Reverse: 5’-CCTTCTCCTGCGGGAATCCAA-3’. 
2. Primer for IFN-β gene 
- Forward: 5′-GACCTGTCAGTTGATGCC-3’ 
- Reverse: 5′- AGTAGATTCACTACCAGTCCC-3’ 
3. Primer for IFN-γ genes 
- Forward: 5′-AGTCTCTTCTTGGATATCTGGAGG-3′ 
- Reverse: 5′-GTGTGATTCAATGACGCTTATGTT-3′ 
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A.2.2 Primers for inflammatory genes 
4. Primer for ICAM-1 gene 
- Forward 5′-CTGTGGCACCGTGCAGTCGTC-3′  
- Reverse 5′-TGGCGGCTCAGTATCTC-3′. 
5. Primer for TNF- α gene 
- Forward 5′- GTCAACCTCCTCTCTGCCGTCAAG -3′  
- Reverse 5′- TCCAAAGTAGACCTGCCCGGACTC -3′. 
A.2.3 Primers for immune response gene 
6. Primer for MHC class-I gene 
- Forward: 5′- CAGAGAGACTCAGGGCCTACC -3′ 
- Reverse: 5′- GCGTCGCGTTCCCGTTCTT -3′ 
A.2.4 Primers for apoptotic genes 
1. Primer for Fas gene 
a. Forward: 5′- CCCAGAATACCAAGTGCAAG -3′ 
b. Reverse: 5′- AGGGTTCCATGTTCACACGAG -3′ 
2. Primer for Caspase-3gene 
a. Forward: 5′- TCTGACTGGAAAGCCGAAACT -3′ 
b. Reverse: 5′- GGATGAACCACGACCCGTCCT -3′ 
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3. Primer for Bax gene 
- Forward: 5′-TTGCCCTCTTCTACTTTGCTA-3′ 
- Reverse: 5′-CCTCAGCCCATCTTCTTCCAG-3′ 
A.2.5 Primers for 18S rRNA gene 
- Forward: 5′-AAGCCATGCATGTCTAAGTACGCA -3′ 
- Reverse: 5′-CAAGTAGGAGAGGAGCGAGCGACC -3′ 
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